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 1  Introduction 
 
1.1  The circulatory system 
 
In our body, there are two major circulatory systems, the blood vascular system and 
the lymphatic vascular system. Their most important function is to carry fluids (blood 
and lymph fluids) and both systems mainly consist of vessels that are lined by a cell 
type called endothelial cells. The blood vascular system is a closed circular system 
that delivers oxygen and nutrients as well as signaling molecules to the body tissue 
and removes tissue waste. The lymphatic system is an open end linear system which 
begins at the peripheral tissues or various organs and ends to its connection to the 
vein. The lymphatic vessels deliver tissue fluids, cells and macromolecules to the 
blood vascular system for recirculation.   
 
1.2  Vasculogenesis, angiogenesis and arteriogenesis 
 
During embryonic development the first step of blood vessel formation is 
characterized by vasculogenesis. Vasculogenesis refers to the in situ differentiation 
of the hemangioblast, a common progenitor of endothelial and hematopoietic cells 
into the angioblast, which migrates and gives rise to the formation of a primitive 
network, the vascular plexus (Carmeliet, 2000). Most important factors involved in 
vasculogenesis are vascular endothelial growth factor (VEGF), its receptors VEGFR1 
and VEGFR2 as well as basic fibroblast growth factor (bFGF), which influence 
angioblast differentiation, and molecules mediating cell-matrix interactions such as 
Integrin subunit α5 and its ligand fibronectin (Carmeliet, 2000). Additionally, during 
the angioblast stage the transcription factor gridlock (Zhong et al., 2000) and 
subsequently members of the ephrin family mediate the fate of endothelial cells to 
become integrated either in arteries or veins (Gale and Yancopoulos, 1999). While 
the term “vasculogenesis” originally described only the embryonic de novo blood
 
vessel formation from angioblasts, it meanwhile refers also to the formation of blood 
vessels in the adult by endothelial progenitor cells or other adult stem cells 
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 (Carmeliet, 2000). During angiogenesis, the vascular plexus expands and remodels. 
Several important key processes are involved in angiogenesis. VEGF as well as 
ANG2 increase the vascular permeability, therefore releaving the path for 
proliferating endothelial cells to migrate. The establishment of blood flow requires the 
formation of a vascular lumen. There is increasing evidence that lumen formation is 
driven by intracellular and intercellular fusion of endothelial vacuoles (Kamei et al., 
2006). Angiogenesis is completed by the recruitment of perivascular cells, which 
stabilize nascent vessels by inhibiting proliferation and migration of endothelial cells.  
 
 
 
.  
Figure 1.1 Formation of a vascular network 
Endothelial progenitors differentiate to arterial and venous EC, which assemble in a primitive 
capillary plexus. Vessels then sprout and become stabilized by SMCs, differentiating from their 
progenitors. HSCs contribute to angiogenesis directly and indirectly, by differentiating to leukocytes 
or platelets. A partial list of molecules is indicated. (Carmeliet, 2003) 
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Subsequent arteriogenesis is characterized by the outgrowth of collateral arteries in 
response to increased luminal shear stress leading to the enlargement of small pre-
existing anastomoses towards large conductance arteries and covering of the 
vessels with a muscular coat (Silvestre et al., 2008).   
Angiogenesis and vasculogenesis are physiological processes during development, 
play essential roles in the recovery of blood flow in ischemic tissues and are 
fundamental steps in tumor growth. Enhancement of angiogenesis and 
neovascularization has been identified as potential therapeutic strategy, for example 
in patients suffering from critical ischemia. In tumor angiogenesis, inhibition of these 
processes leads to repression of tumor growth. 
 
1.2.1 Organization of the vascular system 
 
The vascular system consists of arteries, veins, arterioles and venules as well as 
capillaries. The innermost layer of all vessels is made up from a monolayer of 
endothelial cells (EC), the EC tube. Large and small vessels mainly differ in the 
composition of the surrounding stabilizing cells. Whereas capillaries consist of the EC 
tube surrounded by a sparse layer of pericytes embedded in the EC basement 
membrane, arterioles and venules have an increased coverage of mural cells. Larger 
vessels consist of three specialized layers: an intima composed of endothelial cells, a 
media of smooth muscle cells (SMC) and an adventitia of fibroblasts, together with 
matrix and elastic laminae (Fig. 1.2).  
The advential layer has its own blood supply, known as vasa vasorum that extends in 
part into the media (Jain, 2003). Endothelial-derived factors control SMCs and elastic 
laminae, which in turn contribute to the vessel tone and mediate the control of vessel 
diameter and blood flow. 
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Figure 1.2 Wall composition of nascent versus mature vessels 
A) Nascent vessels consist of a tube of EC. B) Capillaries consist of the EC tube surrounded by a 
sparse layer of pericytes and the EC basement membrane. C) Arterioles and venules have an 
increased coverage of mural cells compared to capillaries. D) The walls of larger vessels consist of 
three specialized layers: an intima composed of endothelial cells, a media of SMCs and an adventitia 
of fibroblasts, together with matrix and elastic laminae. E) Lymphatic capillaries lack pericytes, but 
larger (collecting) lymphatic vessels are invested in a basement membrane. (Jain, 2003) 
 
 
1.2.2 The endothelium 
 
The endothelium is essential for the normal function of the cardiovascular, 
cerebrovascular, renovascular, and pulmonary vascular systems. The vascular 
endothelium is not merely a lining for blood cells and plasma, it is rather a metabolic 
active organ and plays crucial roles in regulating vascular permeability, 
macromolecular transport, vascular tone, inflammation, coagulation, and vascular 
wall structure (Sato, 2001). 5 
 
Vascular permeability, the capacity of blood vessel walls to allow the passage of 
small molecules (ions, water, and nutrients) or even whole cells to the interstitial 
space is regulated by endothelial cell-cell contacts. During inflammation, for example, 
white blood cells interact with endothelial cells via cell adhesion molecules (CAMs) 
and specific receptors, thereby promoting adherens of leukocytes to the activated 
endothelium, transmigration and penetration in areas of infection or tissue damage 
(Patarroyo and Makgoba, 1989). Furthermore, endothelial cells react to mechanical 
forces generated by blood flow under pressure by releasing vasoactive substances. 
Under physiological conditions, endothelial cells continuously release nitric oxide 
(NO) leading to vasorelaxation by relaxing surrounding smooth muscle cells (Ignarro 
et al., 1987). On the other hand, activated endothelium can secrete also 
vasoconstrictors like endothelin-1 (ET-1) that affect differentiation and growth of 
smooth muscle cells (Hirata et al., 1988; Komuro et al., 1988; Yanagisawa et al., 
1988).  Normally, endothelial cells exhibit anticoagulant and antithrombotic properties 
by secreting antiplatelet substances such as PGI2 and NO. However, after vessel 
injury thrombin is generated at the site of endothelial denudation causing a series of 
coagulation responses (Sato, 2001). Additionally, endothelial cells contribute to the 
formation of new vessels. Usually, endothelial cells are quiescent, but still have the 
ability to proliferate and migrate. Angiogenesis, the formation of new capillaries from 
pre-existing vessels mediated by endothelial cells is a fundamental process during 
development and is crucial for recovery after ischemia.  
 
Since the vascular endothelium is sensitive to various stimuli including cytokines, 
oxidized low density lipoprotein (LDL), hypoxia and mechanical stress it is directly 
involved in the development and progression of a variety of severe diseases like 
heart diseases, stroke, venous thombosis, diabetes and tumor growth. With this 
respect, the endothelium represents a biological determinant that could be modulated 
to prevent disease development and progression.   
 
1.2.3 Angiogenesis and disease 
 
As already mentioned in paragraph 1.1.1, angiogenesis, the outgrowth of new 
capillaries from pre-existing vessels, is a major player during development. Over the past decades, however, angiogenesis has been spotlighted on account of its 
contribution in the progression and initiation of severe diseases such as coronary 
artery disease (CAD), cancer, ocular, point and skin disorders or, on the other hand, 
the possibility to improve functional recovery after ischemic disorders. One of the 
most important endothelial mitogens is vascular endothelial growth factor (VEGF), 
which includes a family of three different growth factors involved in vascular and 
lymphangiogenesis. VEGF mRNA is substantially upregulated in most human tumors 
(Ferrara and Davis-Smyth, 1997). Although tumor cells represent the main source of 
VEGF, tumor-associated stroma is also an important site of VEGF production 
(Fukumura et al., 1998). Furthermore, there are high plasma levels of VEGF in tumor 
patients in comparison to healthy controls, which are associated with a poor outcome 
before chemotherapy (Salven et al., 1998).  
 
 
  First studies showed that several tumor cell lines can be substantially growth-
 
Table 1.1 Pro-angiogenic factors 
VEGF: Vascular endothelial growth factor; bFGF: basic fibroblast growth factor; SDF 1: Stromal cell-
derived factor-1; IL-8: Interleukin-8; TGF-β: Transforming growth factor-β; PDGF-BB: Platelet-derived 
growth factor-BB; CAMs: Cell adhesion molecules; RAP1: RAS associated protein 1; PI3K: 
Phosphoinositide 3-Kinase; AKT: Protein Kinase B; ANG2: Angiopoietin 2; FOXO: Forkhead box 
transcription factor class O ; ETS1: V-ets erythroblastosis virus E26 oncogene homolog 1; SIRT1: 
Silent mating type information regulation 2 homolog 1; HIF-1α: Hypoxia inducible factor 1α ; SP1: 
Transcription factor; TIE2: Protein tyrosine kinase; VEGFR-1: VEGF receptor 1; VEGFR-2: VEGF 
receptor 2. 
6 
 7 
 
inhibited by treatment with antibodies against VEGF indicating the involvement of 
VEGF in tumorigenesis (Kim et al., 1993). Since this first studies, intensive effort has 
been undertaken to develop therapeutic strategies to inhibit angiogenesis by using 
VEGF antagonists or antibodies targeting the VEGF receptors (Carmeliet, 2005).  
Furthermore, NO, a gaseous molecule continuously released by endothelial cells 
under physiological conditions, exert pro- and anti-tumorigenic effects. The decision, 
if NO promotes or inhibits tumor progression is dependent on several factors, like the 
activity and localization of the different NO Synthase (NOS) isoforms, concentration 
and duration of NO exposure, and the cellular sensitivity to NO (Fukumura et al., 
2006). Thereby, NO triggers multiple signaling pathways through S-nitrosylation 
and/or cGMP leading either to tumor cell proliferation, migration, invasion and 
increased resistance to apoptosis or tumor cell apoptosis and necrosis (Fukumura et 
al., 2006).  
 
In contrast, stimulation of blood vessel formation in tissue deficient of normal blood 
flow, so-called therapeutic angiogenesis, is a promising intervention for patients 
suffering from severe diseases such as coronary artery disease. However, none of 
the techniques that have been used in VEGF therapy trials,
  including protein, 
plasmid, and adenoviral-based therapies,
 had any significant impact on the amount of 
VEGF in circulating
 blood or in ischemic tissues (Simons, 2005). This might be on the 
one hand attributed to a suboptimal delivery strategy, on the other hand growth factor 
delivery alone might not be sufficient to stimulate the formation of functional vessels. 
Therefore, novel strategies, involving transplantation of bone-marrow-derived cells or 
delivery of molecules stimulating the growth of proximal collateral vessels may be 
required for the future.  
Additional strategies have been developed to target mural cells, hematopoietic cells 
and neoplastic cells. This therapeutical intervention might be also useful for treatment 
of diseases like diabetic retinopathy or age-related macular degeneration (AMD).  
 
 
 
 
 1.3 MicroRNAs 
 
1.3.1 The diverse role of non-coding RNAs  
 
Only less than 1.5% of the human genome encodes protein-coding sequences, 
whereas the vast majority of the human transcriptional output (~ 98 %) is non-coding 
RNA. The work of the recent years suggests a complex role of these non-coding 
RNAs (ncRNAs) on various levels of gene regulation using a wide range of 
mechanisms (Fig. 1.3) (Amaral et al., 2008). Starting with the chromatin architecture, 
Piwi-interacting RNAs (piRNAs) contribute to the formation of euchromatin (Yin and 
Lin, 2007), while small interfering RNAs (siRNAs) are linked to the formation of 
heterochromatin (Buhler and Moazed, 2007). Although there is some evidence for 
the involvement of ncRNAs in epigenetic control, it is so far poorly understood. 
HOTAIR, a 2.2 kilobase ncRNA residing in the HOXC locus, represses transcription 
in trans across 40 kilobases of the HOXD locus. 
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NcRNAs can directly interfere with transcription by 
binding transcription factors or DNA itself. The double-
stranded small RNA NRSE can trigger gene 
expression of neuron-specific genes through 
interaction with NRSF/REST transcriptional machinery,  
Recent examples of the various levels of regulation of 
eukaryotic gene expression and cell biology by ncRNAs. 
dsRNA, double-stranded RNA; HMT, histone 
methyltransferases; HP1, heterochromatin protein 1; PARs, 
promoter-associated RNAs; PcG, Polycomb group proteins; 
RISC, RNA-induced silencing complex; RITS, RNA-induced 
initiation of transcriptional gene silencing; siRNA, small 
interfering RNA; TFIIB, transcription factor IIB; and UCE, 
ultraconserved element (Amaral, 2008) 
Figure 1.3 The world of non-coding RNAs 
 
HOTAIR interacts with Polycomb Repressive Complex 2 (PRC2) and is required for 
PRC2 occupancy and histone H3 lysine-27 trimethylation of the HOXD locus (Rinn et 
al., 2007) known primarily as a negative transcriptional regulator. This interaction 
results in the NRSF/REST complex no longer binding to HDACs, MeCP2, and MBD1, 
thereby switching cofactors from repressors to activators (Kuwabara et al., 2004).  
Additionally, promoter-directed sequence-specific RNAs, e.g. microRNAs (Place et 
al., 2008), have been shown to induce or repress transcription. Moreover, a wide 
class of ncRNAs, microRNAs, are able to regulate gene expression on the posttranscriptional level by binding the target mRNA, thereby leading to translational 
repression or mRNA degradation. 
 
1.3.2 MicroRNA history 
 
The proper regulation of gene expression plays a crucial role in nearly all biological 
processes. Until now the epigenetic control by histone and DNA modification as well 
as transcription factors, which suppress or promote gene expression on the 
transcriptional level, are the best studied mechanisms involved in gene regulation.  
 
 
 
Figure 1.4 Global regulatory network 
Gene expression is regulated on the 
epigenetic level by histone and DNA 
modifications  (1) or on the transcriptional 
level by transcription factors (2). Recent 
studies described a third mechanism in 
which microRNAs inhibit gene expression 
by binding to the 3`UTR of the target mRNA 
(3). (Cheng, 2005) 
 
However, in 1993, Victor Ambros and colleagues first discovered that lin-4, a gene 
known to control timing of C. elegans larval development, does not code for a 
protein, but instead produces a pair of small RNAs. This RNA was shown to be 
approximately 22 nt in length, and has antisense complementarity to multiple sites in 
the 3′ UTR of the lin-14 gene. First studies proposed a model in which lin-4 RNAs 
pair to the lin-14 3`UTR leading to the specific translational repression of lin-14 gene 
thereby triggering the transition from cell divisions of the first laval stage to the 
second (Lee et al., 1993; Wightman et al., 1991; Wightman et al., 1993). The shorter 
lin-4 RNA is now recognized as the founding member of an abundant class of tiny 
regulatory RNAs called microRNAs (miRNAs) (Lagos-Quintana et al., 2001; Lau et 
al., 2001; Lee and Ambros, 2001) representing a new regulatory mechanism to post-
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transcriptionally regulate translational repression or degradation of the target mRNA 
(Bartel, 2004) (Fig. 1.4). So far about 500 human miRNAs have been discovered and 
there is increasing evidence that miRNAs are involved in various biological 
processes such as cardiogenesis, skeletal muscle proliferation and differentiation, 
brain morphogenesis, oncogenesis and hematopoietic lineage differentiation while 
their dysregulation contributes to a variety of human diseases (Chen et al., 2004; 
Chen et al., 2006; Esquela-Kerscher and Slack, 2006; Giraldez et al., 2005; Zhao et 
al., 2007; Zhao et al., 2005). However, microRNAs are not only key regulators in 
animals but also in plants. These miRNAs regulate plant tissue differentiation, 
development and growth, control auxin signal transduction are involved in plant 
response to a variety of abiotic and biotic environmental stresses (Wang and Li, 
2007). 
 
1.3.3 Biogenesis 
 
MicroRNAs are generated in a two-step processing pathway mediated by two major 
enzymes, Dicer and Drosha, which belong to the class of RNAse III endonucleases. 
Drosha is part of a multiprotein complex, the microprocessor, which mediates the 
nuclear processing of the primary miRNAs (pri-miRNA) into stem-loop precursors of 
approximately 60-70 nucleotides (pre-miRNA) (Lee et al., 2003). The treatment of 
Hela cells with RNA interference against Drosha results in the strong accumulation of 
pri-miRNA and the reduction of pre-miRNA and mature miRNA (Lee et al., 2003). 
Exportin-5 mediates the nuclear export of correctly processed miRNA precursors in a 
RAN-GTP dependent manner (Lund et al., 2004). In the cytoplasm, the pre-miRNA is 
cleaved by Dicer into the mature 22 nucleotide miRNA (Bartel, 2004). Dicer was 
originally recognized for its role in generating small interfering RNAs (siRNA) 
(Bernstein et al., 2001) and was later shown to be also involved in miRNA maturation 
(Grishok et al., 2001). The mature miRNA incorporates as single-stranded RNA into a 
ribonucleoprotein complex, known as the RNA-induced silencing complex (RISC) 
(Hammond et al., 2001).  
 
Figure 1.5 microRNA biogenesis 
miRNAs are transcribed by Pol II into the primary miRNA (pri-miRNA), which is processed by the 
RNAse III endonuclease Drosha into a 60-70 nucleotide stem loop intermediate (pre-miRNA). The 
pre-miRNA is transported to the cytoplasm by Exportin-5 and its cofactor RAN-GTP, where it is 
cleaved by Dicer into the mature miRNA. The incorporation of the mature miRNA into the RISC 
complex directs the miRNA to the target mRNA and leads to translational repression or mRNA 
degradation. 
 
This complex directs the miRNA to the target mRNA, which leads either to 
translational repression or degradation of the target mRNA (Bartel, 2004) (Fig. 1.5). 
 
1.3.4 Target prediction and regulation 
 
A central goal for understanding microRNA function is to understand how they 
recognize their target message and how the binding of the microRNA to the target 
site in the 3`UTR leads to downregulation. Conserved Watson-Crick pairing to the 
5`end of the microRNA enables prediction of targets. However, in contrast to small-
interfering RNA (siRNA), which binds complementary to the target mRNA, thereby 
leading to mRNA degradation, miRNA has rarely perfect complementarity to the 
target mRNA. Several different algorithms, either based on the complementarity or  
thermodynamic-based algorithmy accessible on various online databases (e.g. 
11 
 TargetScan, PicTar, miRanda, Diana-microT) have been developed to overcome the 
problem of false-positive predictions. In the following, the algorithm used for target 
prediction with the TargetScan database will be introduced in greater detail (Grimson 
et al., 2007). Complementary microRNA binding sites, so called seed sequences, in 
the 3´UTR of target mRNA are classified in three different groups:  7mer-A1, 7mer-
m8 and 8mer (Fig.  1.6). The 7mer-A1 refers to the binding of the miRNA nucleotides 
2-7 to the target mRNA augmented by an A at target position 1. Another 7mer is the 
7mer-m8 with a direct match of miRNA nucleotides 2-8. The 8mer is a combination of 
the 7mer-A1 and 7mer-m8 with a direct match at position 2-8 and an additional A at 
target position 1. However, only a minority of single target sites induces the 
degradation of the target mRNA (19% 7mer-A1, 25% 7mer-m8 and 43% 8mer) 
suggesting that multiple target sites are associated with higher mRNA stability. 
 
 
Canonical miRNA complementary sites. The 6mer 
is the perfect 6 nt match to the miRNA seed 
(miRNA nucleotides 2–7). The best 7mer site, 
refered to here as the 7mer-m8 site, contains the 
seed match augmented by a match to miRNA 
nucleotide 8. Also effective is another 7mer, the 
7mer-A1 site, which contains the seed match 
augmented by an A at target position 1. The 8mer 
site comprises the seed match flanked by both the 
match at position 8 and the A at position 1. 
(Grimson, 2007) 
 
 
 
Figure  1.6 Downregulation of messages 
with 6-8mer sites 
 
Indeed, multiple target sites show a multiplicative effect meaning that the repression 
for a gene with two different target sites matches the result anticipated by multiplying 
the repression from two single sites. However, the repression tends to be even 
stronger when the two independent target sites are closely spaced within 100 
nucleotides. An additional requirement for sufficient downregulation is Watson-Crick 
pairing close to the 3`end of the microRNA between nucleotides 12-17. Apart from 
12 
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sequence specificity of the target site its localization in the 3`UTR is also an 
important factor. Effective target sites preferentially reside within a local AU-rich 
context, which might be associated with weaker secondary structure in the vicinity of 
the site and thus increased accessibility to the seed site. Further on, effective sites 
are favorable located close to both ends of the 3`UTR, whereas binding sites less 
than 15 nucleotides from the stop codon are less effective, probably because of the 
local interference of the microRNA with adjacent ribosomes bound to the open 
reading frame of the mRNA. Beside the previously described characteristics of 
miRNA mRNA binding, the secondary structure and therefore the accessibility of the 
mRNA has been also shown to play a crucial role in target prediction (Zhao et al., 
2005). Using mFold, Zhao et al. analysed the binding sites of all identified targets and 
found, that all binding sites are located in unstable regions with low free energy (∆G) 
suggesting a locally linear miRNA-binding site.    
 
Published studies indicate that miRNAs bound to the target mRNA repress protein 
expression in four distinct ways (Eulalio et al., 2008) (Fig. 1.7): The postinitiation 
mechanisms describes a model in which microRNAs repress translation of target 
mRNAs by blocking translation elongation or by promoting premature dissociation of 
ribosomes (ribosome drop-off). The cotranslational protein degradation model 
proposes that translation is not inhibited, but rather the nascent polypeptide chain is 
degraded cotranslationally. The putative protease is unknown. On the other hand 
microRNAs interfere with a very early step of translation, prior to elongation (initiation 
mechanisms). This model suggests a key role of Argonaut proteins, which either 
compete with eIF4E for binding to the cap structure, recruit eIF6, which prevents the 
large ribosomal subunit from joining the small subunit or prevent the formation of the 
closed loop mRNA configuration by an ill-defined mechanism that includes 
deadenylation. 
   
B) Cotranslational protein degra-
dation.  C–E) Initiation mechan-
isms.  F) MicroRNA-mediated 
mRNA decay. (Eulalio, 2007) 
 
Figure 1.7  Mechanisms of 
miRNA-mediated gene 
silencing 
A) Postinitiation mechanisms.  
 
Beside the translational repression microRNAs mediate mRNA decay by triggering 
deadenylation and subsequent decapping of the mRNA target. Proteins required for 
this process include components of the major deadenylase complex (CAF1, CCR4, 
and the NOT complex), the decapping enzyme DCP2, and several decapping 
activators.   
 
1.3.5 Regulation of microRNA activity 
 
Considering the fact that microRNAs are involved in a wide variety of physiological 
processes, it is not surprising that the biogenesis and activity of microRNAs is a 
tightly regulated process. Recent studies indicate that a large subset of microRNAs is 
associated with CpG islands indicating that these genes represent candidate targets 
for DNA methylation (Weber et al., 2007). Treatment of cells with a combination of 
inhibitors of DNA methylation and histone deacetylation activates the expression of 
14 
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particular microRNAs that may act as tumor suppressors (Saito et al., 2006). 
Moreover, it was demonstrated that various microRNA genes are affected by 
epigenetic inactivation due to aberrant hypermethylation and that this is an early and 
frequent event in breast cancer development (Lehmann et al., 2008). However, 
microRNA regulation is not only restricted to the level of epigenetic control, but also 
takes place during microRNA biogenesis. Thus it has been shown that Lin28, a 
developmentally regulated RNA-binding protein, selectively inhibits the processing of 
pri-let-7 by sufficiently blocking the microprocessor-mediated cleavage in embryonic 
stem cells (Viswanathan et al., 2008). In contrast, receptor-regulated SMAD proteins 
(R-SMAD) are capable to stimulate processing of the pri-miR-21 by binding the 
microprocessor complex in human vascular smooth muscle cells (Davis et al., 2008). 
Furthermore, several microRNAs are modified by RNA editing, leading either to 
changes in RNA stability or target selection (Kawahara et al., 2007; Knight and Bass, 
2002). Finally, microRNA activity is regulated on the level of microRNA to target 
mRNA binding. RNA-binding proteins associate with the target sequence in the 
3`UTR of mRNAs, thereby preventing the binding of the specific microRNA 
(Bhattacharyya et al., 2006; Davis et al., 2008) 
 
1.3.6 Role of Dicer and Drosha in endothelial cells 
 
Dicer, which mediates the cytoplasmatic cleavage of the precursor miRNA into the 
mature miRNAs has been shown to be implicated in several physiological processes 
such as heart function (Chen et al., 2008), chondrocyte proliferation and 
differentiation (Kobayashi et al., 2008), neuronal survival (Schaefer et al., 2007), 
immune regulation (Cobb et al., 2006), brain morphogenesis (Giraldez et al., 2005), 
skin morphogenesis (Yi et al., 2006) as well as angiogenesis (Suarez et al., 2007; 
Yang et al., 2005) . Dicer is constitutively expressed in endothelial cells and its 
expression is not altered in response to stimuli, such as VEGF (Suarez et al., 2007). 
Previous publications have described a crucial role of the miRNA-regulating enzyme 
Dicer in angiogenesis in vitro and in vivo. Thus, Dicer
ex1/2 mutant mice display 
angiogenic defects in embryos and yolk sacs, while vasculogenesis and initial steps 
of angiogenesis proceed normally (Yang et al., 2005). Consistently, in zebrafish, the 
blood circulation is disrupted in dicer mutants (Giraldez et al., 2005). Deletion of 16 
 
Dicer in endothelial cells impairs the development of capillary-like structures and 
exhibits an anti-proliferative effect (Suarez et al., 2007). The migration of Dicer-
deficient endothelial cells on collagen matrix could be shown to be not affected 
(Suarez et al., 2007). 
Furthermore, Dicer knockdown causes profound dysregulation of angiogenesis-
related genes in vitro and  in vivo. Despite the requirement of Dicer for 
vascularization, crucial regulators of angiogenesis, for instance vascular endothelial 
growth factor (VEGF)  and its receptors  FLT1  and  KDR,  have been shown to be 
upregulated by depletion of Dicer (Suarez et al., 2007; Yang et al., 2005) . 
Furthermore, protein levels of the angiopoietin receptor TIE1, expressed in vascular 
endothelium during angiogenesis, are decreased in Dicer 
ex1/2 embryos (Yang et al., 
2005), whereas its expression is strongly enhanced in Dicer-depleted cultured 
endothelial cells (Suarez et al., 2007). This phenomenon might be explained by the 
complex mixture of miRNAs being spatiotemporally expressed during development 
compared to isolated endothelial cells in culture.   
In contrast to Dicer, the involvement of Drosha in angiogenic processes was 
unknown at the beginning of this project.  
 
1.3.7 Specific microRNAs involved in angiogenesis 
 
The majority of miRNAs are expressed in many cell types with variations in the 
expression levels, whereas about one-third of microRNAs show substantially tissue-
specificity. When this study was initiated, the expression profile of miRNAs in EC was 
still unknown. Meanwhile, we and others profiled microRNA expression in EC in order 
to identify miRNAs involved in the control of EC biology (Poliseno et al., 2006; 
Suarez et al., 2007). 
Analyzing the two published expression patterns reveals that eight miRNAs are 
highly expressed in human umbilical cord endothelial cells: let-7b, miR-16, miR-21, 
miR-23a, miR-29, miR-100, miR-221, and miR-222 (Poliseno et al., 2006; Suarez et 
al., 2007). Among the highly expressed miRNAs, only a few have been functionally 
characterized so far.   
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First studies addressed the role of highly expressed miR-221 and miR-222 in 
endothelial cells. Transfection of endothelial cells with miR-221 and miR-222 inhibits 
in vitro angiogenesis by blocking tube formation and migration and reduced wound 
healing of endothelial cells in vitro (Poliseno et al., 2006). MiR-221 and miR-222 
decrease protein levels of c-kit, the receptor for stem cell factor, whereas mRNA 
levels were not affected indicating that miR-221/222 target c-kit expression by 
blocking protein translation (Poliseno et al., 2006). In addition, miR-221 and miR-222 
overexpression has been shown to indirectly reduce the expression of the endothelial 
nitric oxide synthase (eNOS) in the context of Dicer silencing (Suarez et al., 2007). 
Given that eNOS contributes to endothelial cell functions, its reduction by miR-
221/222 may have caused the functional impairment such as inhibited tube 
formation, migration and wound healing observed in miR-221/222 transfected 
endothelial cells. Since miR-221 and miR-222 target at least two important regulators 
of pro-angiogenic endothelial cell function, c-kit and eNOS, it might be an attractive 
tool to block angiogenesis. In addition, miRNAs 221 and 222 also inhibit cell 
proliferation and reduce c-kit expression in hematopoietic progenitor cells (Felli et al., 
2005), which can contribute to vessel growth. Whether inhibition of miR-221/222 
might be useful to enhance therapeutic angiogenesis in vivo (e.g. in ischemic tissues) 
remains to be elucidated.  Moreover, in order to use miRNAs as therapeutic tools the 
complete spectrum of miRNA targets in different tissues needs to be specified in 
detail. Indeed, miR-221 and miR-222 exhibit opposing effects on proliferation of 
cancer cells in contrast to endothelial cells. While high expression of miR-221/222 
blocked angiogenesis in endothelial cells these miRNAs promoted proliferation in 
cancer cells by targeting the cell cycle inhibitor p27 (le Sage et al., 2007)  suggesting 
a cell type specific regulation of proliferation. MiR-130a downregulates the anti-
angiogenic homeobox proteins GAX (growth arrest homeobox) and HoxA5, and 
functionally antagonized the inhibitory effects of GAX on endothelial cell proliferation, 
migration and tube formation and the inhibitory effects of HOX A5 on tube formation 
in vitro (Chen and Gorski, 2008). MiR-126 inhibited the expression of vascular cell 
adhesion molecule 1 (VCAM-1), which mediates leukocyte adherence to endothelial 
cells. Thus, decreasing miR-126 in endothelial cells increases TNF-α-stimulated 
VCAM-1 expression and enhances leukocyte adherence to endothelial cells (Harris 
et al., 2008). 18 
 
Two other miRNAs, which might be involved in angiogenesis, are miR-15b and miR-
16. Although the direct effect of miR-15b and miR-16 in endothelial cells has not 
been elucidated, both miRNAs are downregulated by hypoxia in a carcinoma cell line 
(Hua et al., 2006). MiR-15b and miR-16 control the expression of VEGF, a key pro-
angiogenic factor particularly involved in tumor angiogenesis (Hua et al., 2006). 
These data indicate that hypoxia-induced reduction of these miRNAs contributes to 
an increase in VEGF levels. Interestingly, miR-15b and miR-16 induce apoptosis of 
leukemic cells by targeting the anti-apoptotic protein BCL2, block cell cycle 
progression and are frequently downregulated in chronic lymphocytic leukemia 
(Cimmino et al., 2005; Linsley et al., 2007). Therefore, one may speculate that miR-
15b/miR-16 overexpression might be an attractive anti-tumor strategy by targeting 
tumor cell survival and proliferation and by blocking VEGF-mediated angiogenesis.  
 
1.3.8 Role of microRNAs in diseases 
 
Whereas several years ago microRNAs were supposed to be fine tuners, just 
modulating different processes, emerging evidence suggest a key role of microRNAs 
in nearly all physiological and pathophysiological processes.  About one- third of the 
microRNAs show substantially tissue specificity, while the others vary in their 
expression levels but are not particularly cell or tissue-specific. The involvement of 
microRNAs was shown for stem cell biology, meiotic spindle formation and 
chromosome organization, skeletal muscle proliferation and differentiation as well as 
cardiac function, hematopoiesis and immunity and the nervous system. Hence it is 
not surprising that microRNAs came under close investigation in a variety of 
diseases. 
 
Several microRNAs have been identified as crucial players in the development of 
heart failure. MiR-195 is consistently overexpressed in human and rodent 
hypertrophic hearts leading to dilated cardiomyopathy and heart failure, probably by 
targeting multiple prosurvival genes (van Rooij et al., 2006). MiR-208 is required for 
stress-dependent cardiac hypertrophy and fibrosis by blocking THRAP1 expression 
and therefore β-MHC upregulation (van Rooij et al., 2007). MiR-1 has a crucial 
function in cardiac development and contractility by targeting the transcription factor 19 
 
HAND2 and IRX5 as well as the potassium channel KCND2 (Zhao et al., 2007; Zhao 
et al., 2005). MiR-133 is downregulated in human heart disease as well as three 
models of cardiac hypertrophy (Care et al., 2007). These data suggest a role of miR-
133 in the inhibition of remodeling processes and hypertrophy.  
In addition, there is evidence for the participation of microRNAs in neuronal diseases 
like Alzheimer and Parkinson´s disease. MiR-133b is specifically expressed in 
midbrain dopaminergic neurons and is deficient in midbrain tissue from patients 
suffering from Parkinson´s disease. MiR-133b regulates the maturation and function 
of midbrain dopaminergic neurons including PITX3 for fine tuning of dopaminergic 
behaviors like locomotion (Kim et al., 2007). Loss of miR-29a/b-1 in the brain 
contributes to increased BACE1 and Aβ levels, which in turn has been shown to be 
associated with sporadic Alzheimer disease (Hebert et al., 2008). Furthermore, the 
implication of several microRNAs was shown for infectious diseases (Cullen, 2006).  
 
Most studies of the last decade, however, focused on the contribution of microRNAs 
to the initiation and progression of cancer. MicroRNAs involved in cancer are divided 
in two groups: microRNAs located in portions of chromosomes deleted in cancers 
function as tumor suppressors and microRNAs located on genomic regions amplified 
in cancer and function as oncogenes, so-called oncomirs. Members of the let-7 
family targeting the Ras oncogenes and the miR-15a-miR-16-1 cluster targeting the 
anti-apoptotic gene BCL2 seems to act as tumor suppressors. On the other hand 
miR-21 and members of the miR-17-92 cluster are highly overexpressed in many 
solid tumor types and have been shown to act as oncogenes.    
      
1.3.9 miR-17-92 cluster 
 
The miR-17-92 cluster is a polycistronic miRNA gene encoding the miRNAs, miR-17-
5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b and miR-92-a-1 (Venturini et 
al., 2007) grouped on chromosome 13. The sequences of the mature miRNAs as 
well as their organization are highly conserved between all vertebrates.  
  
 
Figure 1.8 Genomic organization of three homologues microRNA cluster 
A) The genomic organization and primary transcript structures of the human miR-17-92, miR-106a-
363, and miR-106b-25 clusters. The miR-106a-363 primary transcript has not been characterized. 
B) Based on their seed sequences—which are the regions considered most important for target 
selection (nucleotides 2–7; shown in blue)—the miRNAs of these clusters can be grouped into four 
families: the miR-17 family (miR-17, miR-20a/b, miR-106a/b, and miR-93); the miR-18 family (miR-
18a/b); the miR-19 family (miR-19a/b); and the miR-25 family (miR-25, miR-92a, and miR-363). 
(Mendell, 2008) 
 
The miR-17-92 cluster has two paralogs in mammals: the miR-106a-363 cluster on 
the X-chromosome encoding miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-a-2 
and miR-363 and the miR-106b-25 cluster on chromosome 7 encoding miR-106b, 
miR-93 and miR-25 (Fig. 1.8). While miR-17-92 and miR-106b-25 clusters are 
abundantly expressed across many tissues, the miR-106a-363 cluster is in most 
cases undetectable or expressed at very low levels. Consistently, a deletion of the 
miR-106a-363 cluster or the miR-106b-25 cluster has no obvious phenotypic 
consequences, whereas deletion of miR-17-92 cluster leads to death shortly after 
birth. The phenotype is often characterized by lung hypoplasia and a ventricular 
septal defect. Whereas little is known so far about the miR-106a-363 and miR-106b-
25 clusters, the functional impact of the whole miR-17-92 cluster as well as several 
mature microRNAs expressed from the cluster are analyzed in more detail. 
20 
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It was shown, that miR-17-92 is highly expressed in embryonic stem cells, with 
expression levels decreasing during embryonic development in mice (Thomson et al., 
2004). These results support the idea that high levels of miR-17-92 promote the 
proliferation of progenitor cells and inhibit their differentiation. Additionally, a 
significant upregulation could be observed in Myc-induced tumors and miR-17-92 
has been shown to specifically target anti-angiogenic proteins (Dews et al., 2006). 
Specific evaluation of the targets revealed that miR-18 suppresses connective tissue 
growth factor (CTGF) expression, whereas miR-19 targets the potent angiogenesis-
inhibitor thrombospondin-1 (TSP1) (Dews et al., 2006). MiR-20 and miR-92 do not 
affect the expression levels of the thrombospondin type 1 repeats-containing 
proteins. Transgenic overexpression of miR-17-92 in lungs displayed an abnormal 
lethal phenotype with numerous proliferative epithelial cells that retain high levels of 
SOX9 and inhibited differentiation of proximal epithelial cells (Lu et al., 2007b). 
Transgenic mice overexpressing miR-17-92 in lymphocytes developed 
lymphoproliferative disease and autoimmunity and died prematurely, probably by 
suppressed expression of the tumor suppressor PTEN and the proapoptotic protein 
Bim (Xiao et al., 2008). Consistently, ablation of the miR-17-92 cluster led to 
increased levels of Bim and inhibited B-cell development at the pro-B to pre-B 
transition (Ventura et al., 2008).  
 
So far, there is only sparse information about the transcriptional regulation of the 
miR-17-92 cluster. C-myc, a factor frequently hyperactive in cancer cells was 
reported to transactivate the miR-17-92 cluster. Moreover, members of the E2F 
family of transcription factors, which are critically involved in cell cyle and  
apoptosis, are regulated by the miR-17-92 cluster, but in turn can directly activate the 
expression of these microRNAs as a positive feedback.   
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1.4  Aim of the study 
 
MicroRNAs are small non-coding RNAs regulating gene expression on the 
posttranscriptional level by binding to the target mRNA thereby promoting 
translational repression or mRNA decay. The research of the last decade 
demonstrates that microRNAs are involved in nearly all physiological and 
pathophysiological processes, e.g. differentiation, oncogenesis and cardiogenesis by 
regulating whole networks of genes. However, at the beginning of this study nothing 
was known about the specific role of microRNAs in endothelial cells as well as in 
endothelial cell dependent processes like angiogenesis and neovascularization. 
Hence, following aspects were specifically studied: 
 
1. Dicer and Drosha are the major microRNA-processing enzymes. Using siRNA 
targeting Dicer and Drosha, we planned to analyse the general role of microRNAs in 
endothelial cell biology. 
 
2. We aimed to determine the microRNA expression profile in EC in order to identify 
specific microRNAs, which are involved in EC biology. Based on the identification of 
the highly expressed microRNA, miR-92a, we proposed to study the role of miR-92a 
in angiogenesis and neovascularization in vitro and in vivo in more detail.   23 
 
2  Material and Methods 
 
2.1  Cell culture of HUVEC 
 
Pooled human umbilical vein endothelial cells (HUVEC) were purchased from 
Cambrex and cultured in endothelial basal medium (EBM; Cambrex) supplemented 
with hydrocortisone, bovine brain extract, epidermal growth factor, antibiotics and 
10% fetal calf serum (FCS; Gibco) at 37°C, 5% CO2  air humidity until the third 
passage. For passaging, cells were washed with 10 ml phosphate buffer saline and 
detached with 3 ml Trypsin/EDTA. After removal of Trypsin, cells were resuspended 
in 10 ml medium and seeded in new T-75 cell culture flasks. For experiments, cells 
were seeded in 6 cm culture dishes for at least 24-48 hours to the indicated 
confluency.  
 
Cells  Description 
HUVEC  Human umbilical vein endothelial cells (Lonza) 
HMVEC  Human microvasculare endothelial cells (Lonza) 
HEK293  Human embryonal kidney epithelial cells (transformed cell line) 
HCM  Human cardiac myocytes 
HAoSMC  Human aortic smooth muscle cells (PromoCell) 
HAoAF  Human aortic adventitial fibroblasts (PromoCell) 
CD34+ 
Cells expressing CD34 on the cell surface isolated from peripheral 
blood 
 
Table 2.1 Cell types  
2.2  Cell culture of HEK293 
 
HEK293 were cultivated in DMEM 4500 including supplements (table 2.2) at 37°C, 
5% CO2  
air humidity. For passaging, cells were washed with 10 ml PBS and detached with 3 
ml Trypsin/EDTA. After removal of Trypsin, cells were resuspended in 10 ml medium 24 
 
and seeded in new T-75 cell culture flasks. For transfection, cells were seeded in 24-
well plates for 24 hours. 
2.3 Growth  media 
 
Growth media used for cultivation of human cells are listed below. 
 
Cells  Medium  Supplements 
HUVEC 
Endothelial basal medium (EBM), 
Cambrex 
10% fetal calf serum (FCS), 
Boehringer Mannheim, hEGF (10 
µg/ml), hydrocortisone (1 µg/ml), 
Bovine brain extract (3 µg/ml), 
Gentamycin sulfate (50 µg/ml), 
Amphotericin-B (50 mg/ml), Cambrex 
HMVEC 
Endothelial basal medium-2 (EBM-2), 
Cambrex 
10% FCS, Boehringer Mannheim, 
EGM
®-MV Bullet Kit, Cambrex 
HEK293 
DMEM 4500 Glucose with Glutamax, 
Gibco 
25% FCS, 2.5% NEAA Gibco 
EPC 
Endothelial basal medium (EBM), 
Cambrex 
20% fetal calf serum (FCS), 
Boehringer Mannheim, hEGF (10 
µg/ml), hydrocortisone (1 µg/ml), 
Bovine brain extract (3 µg/ml), 
Gentamycin sulfate (50 µg/ml), 
Amphotericin-B (50 mg/ml), Cambrex 
HCM  Myocyte growth medium, PromoCell 
Supplement mix/Myocyte growth 
medium, PromoCell 
HAoSMC 
Smooth muscle cell growth medium 2, 
PromoCell 
Supplement Mix/ Smooth muscle cell 
growth medium 2, PromoCell 
HAoAF 
Fibroblast growth medium 2, 
PromoCell 
Supplement Mix/ Fibroblast growth 
medium 2, PromoCell 
 
Table 2.2 Growth media 
 
2.4  Transfection of oligonucleotides 
 
For the suppression of expression of specific genes or microRNAs, HUVEC were 
transfected with siRNA (small interfering RNA) or 2`O-methyl antisense 
oligoribonucleotides (Table 2.3). Therefore, cells seeded in 6 cm dishes (3.1 x 10
5 
cells/well) were grown to 60-70% confluence and transfected either with 60 nM 
siRNA or 50 nM 2`O-methyl antisense oligoribonucleotides using GeneTrans II
® 25 
 
(MoBiTec) according to the manufacturer´s protocol. Control sequences, which do 
not bind endogenous mRNAs or miRNAs  were used.  
2.5  Transfection of pre-miRNA 
 
For overexpression of miRNAs, HUVEC were seeded in 6 cm dishes (3.5 x 10
5 
cells/well) and grown to 50% confluence. 10nM of the precursor or control pre-miR 
(Ambion) were transfected with Lipofectamine RNAiMAX (Invitrogen) according to the 
manufacturer´s protocol.  
 
siRNA  Sequence  Company
Dicer I  UGCUUGAAGCAGCUCUGGA  Eurogentec 
Dicer II  UUUGUUGCGAGGCUGAUUC  Eurogentec 
Drosha I  AACGAGUAGGCUUCGUGACUU  Eurogentec 
Drosha II  AAGGACCAAGUAUUCAGCAAG  Eurogentec 
Integrin α5  UCCUUAAUGGCUCAGACAU Qiagen 
scrambled UCAAGAAGCCAAGGAUAAU  Eurogentec 
2`O-methyl 
oligoribonucleotides  Sequence  Company
GFP AAGGCAAGCUGACCCUGAAGUU VBC  Biotech 
92a CAGGCCGGGACAAGUGCAAUA  VBC  Biotech 
let-7f AACUAUACAAUCUACUACCUCA  VBC  Biotech 
27b GCAGAACUUAGCCACUGUGAA VBC  Biotech 
151 CCUCAAGGAGCUUCACUCUAGU  VBC  Biotech 
191 AGCUGCUUUUGGGAUUCCGUUG VBC  Biotech 
214 CUGCCUGUCUGUGCCUGCUGU VBC  Biotech 
222 GAGACCCAGUAGCCAGAUGUAGCU  VBC  Biotech 
 
Table 2.3 Oligonucleotides used for transfection 
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2.6 RNA  isolation 
 
RNA for quantification of gene expression from human cells was isolated using the 
RNeasy kit (Qiagen). Trizol (Sigma) was used for quantification of microRNAs and 
RNA isolation from animal tissue. Cells or tissue were lysed in a defined volume of 
Trizol, mixed with chloroform and centrifuged. The upper clear phase contained the 
RNA, which was precipitated with isopropanol and washed with 75% ethanol. The 
pellet was resuspended in a defined volume of H2O.  
 
2.7  RT-PCR and real time PCR 
 
In order to analyse the expression of specific genes, 1 µg of RNA was reverse 
transcribed into cDNA and subjected either to semiquantitative end-point PCR or 
quantitative real time PCR (Table 2.4). As loading control GAPDH was used. The 
semiquantitative analysis of the PCR was performed densitometrically after running 
an agarose gel using Scion Image software (Scion Corporation). Quantitative real 
time PCR was performed using the LightCycler
®  SYBR Green
plus I Kit (Roche), 
LightCycler 1.2 and LightCycler 3 software. To assess the differential miRNA 
expression in HUVEC transfected with 2`O-methyl antisense oligoribonucleotides or 
pre-miRNAs, we isolated total RNA using Trizol 24 h after transfection. 
 
PCR  sense (5` Æ 3`)  antisense (5 Æ 3`) 
Human 
Dicer 
CAAGTGTCAGCTGTCAGAACTC 
CAATCCACCACAATCTCACA
TG 
Human 
Drosha 
CACCTGTTCTAGCAGCTCAGAC 
CTCCTCCCACTGAAGCATAT
TG 
Mouse 
Integrin α5 
CATTTCCGAGTCTGGGCCAA 
TGGAGGCTTGAGCTGAGCT
T 
GAPDH 
TCACCATCTTCCAGGAGCGAGAT
C 
GAGACCACCTGGTGCTCAG
TGTAG 
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Cloning  sense (5`Æ 3`)  antisense (5` Æ 3`) 
Integrin α5 
seed 4x 
AGCTTTTTATTGCACTTGCAACAG
AGTTTATTTATTGCACTTGCAACA
GAGTTTATTTATTGCACTTGCAAC
AGAGTTTATTTATTGCACTTGCAA
CAGAGTTTAA 
CTAGTTAAACTCTGTTGCAA
GTGCAATAAATAAACTCTGT
TGCAAGTGCAATAAATAAAC
TCTGTTGCAAGTGCAATAAA
TAAACTCTGTTGCAAGTGCA
ATAAAA 
Integrin α5 
seed mm 
4x 
AGCTTTTTATTACGCTTACAAAAG
AGTTTATTTATTACGCTTACAAAA
GAGTTTATTTATTACGCTTACAAA
AGAGTTTATTTATTACGCTTACAA
AAGAGTTTAA 
CTAGTTAAACTCTTTTGTAA
GCGTAATAAATAAACTCTTT
TGTAAGCGTAATAAATAAAC
TCTTTTGTAAGCGTAATAAA
TAAACTCTTTTGTAAGCGTA
ATAAAA 3 
 
Table 2.4 Primer for PCR and cloning 
 
RT-PCR was performed using the mirVana™ qRT-PCR miRNA Detection Kit 
(Ambion) and primer sets for specific miRNAs or U6 as loading control (Ambion) (one 
cycle: 3 min at 95°C, 20 cycles: 15 seconds at 95°C, 30 seconds at 60°C). 
 
2.8  Stem loop RT and quantitative PCR of miRNAs 
 
Total RNA was isolated using Trizol. 100 ng RNA was reverse transcribed into cDNA 
in a pulsed RT reaction using specific stem-loop Primer containing the binding site of 
probe #21 (Universal Probe Library, Roche) as described by Wu et al., 2007.   
Subsequent real-time PCR using UPL probe #21 (Roche) and specific primer was 
performed on LightCycler 1.2 (Roche). Primer sequences used are listed in table 2.5.  
 (Varkonyi-Gasic et al., 2007). 
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2.9  MicroRNA expression analysis 
 
Total RNA from HUVEC was isolated using TRIZOL. The expression of 360 mature 
human miRNAs in HUVEC was profiled using real-time PCR (DNAvision, Belgium). 
Gene expression data were normalized to RNU48. The relative expression was 
determined for 23 of the 360 miRNAs using the formula 2
-ΔCt. 
 
MicroRNA  Stem loop primer   
miR-92a 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACC
AGGCC 
 
miR-92b 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACG
GAGG 
 
miR-93 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACC
TACCT 
 
miR-18a 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACC
TATCT 
 
miR-19a 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACT
CAGTT 
 
miR-24 
GTTGGCTCTGGTGCAGGGTCCG
AGGTATTCGCACCAGAGCCAACC
TGTTC 
 
U48 
GTTGGCTCTGGTGCAGGGTCCGAG
GTATTCGCACCAGAGCCAACGGTCA
G 
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Real time 
PCR 
sense (5` Æ 3`)  antisense (5` Æ 3`) 
miR-92a CGGCGGTATTGCACTTGTCCC GTGCAGGGTCCGAGGT 
miR-92b CGCGGTATTGCACTCGTCCCG GTGCAGGGTCCGAGGT 
miR-93 CGCCCAAAGTGCTGTTCGTGC GTGCAGGGTCCGAGGT 
miR-18a CGCCTAAGGTGCATCTAGTGC  GTGCAGGGTCCGAGGT 
miR-19a GCCGCCTGTGCAAATCTATGCAA GTGCAGGGTCCGAGGT 
miR-24 CGCGGTGGCTCAGTTCAGCAG GTGCAGGGTCCGAGGT 
U48 GAGTGATGATGACCCCAGGTAA GTGCAGGGTCCGAGGT 
 
Table 2.5 Primer for qRT-PCR 
2.10  MicroRNA array analysis 
 
Total RNA from HUVEC was isolated using Trizol (Invitrogen) according to the 
manufacturer´s protocol. MicroRNA expression profiling of 344 microRNAs was 
performed by microRNA profiling service (Exiqon) using miRCURY LNA arrays. 
 
2.11 Protein  isolation 
 
Cells were washed with cold phosphate buffer, pelletized and resuspended in 150 µl 
RIPA buffer (Sigma) containing protease inhibitor cocktail (Roche) and 1mM PMSF. 
After 20 min incubation on ice the protein lysated was separated from the insoluble 
debris by centrifugation (20.000 x g, 15 min, 4°C). Protein concentration was 
determined by mixing 2 µl protein lysate or 2 µl lysis buffer as control with 798 µl H2O 
and 200 µl Bradford reagent (Biorad). Absorption was measured in the photometer at 
λ = 595 nm. Concentration was measured using a bovine serum albumine (BSA) 
standard curve.   
 
 
 30 
 
2.12  SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein lysates were mixed with 4x sample buffer (250 mM Tris/HCl pH 6.8, 8% SDS, 
40% glycerine, 0.04% bromine phenol blue, 200 mM DTT) and boiled 5 min at 
100°C. The separation of the proteins occurred by discontinuous SDS-PAGE, 
whereas proteins were first focussed by the stacking gel (1 M Tris/HCl pH 6.8, 0.4% 
SDS) and separated by size in the separating gel (1.5 M Tris/HCl pH 8.8, 0.4% SDS) 
using the Mini Protean II gel electrophoresis system (Biorad). Proteins in the stacking 
gel were run at 80 V, in the separating gel at 120 V. The running buffer consisted of 
0.25 M Tris, 0.96 M glycin and 1% SDS. 
 
2.13 Western  blot  analysis 
 
Proteins separated by SDS-PAGE were blotted onto PVDF or Nitrocellulose 
membranes and immobilized. The PVDF membrane was activated by incubation for 
1 min in methanol. Gel, membranes and Whatman papers were equilibrated in 
transfer buffer (0.05 M Tris, 0.038 M glycin, 0.1% SDS, 20% methanol) and placed 
bubble free within two scotch pads. An electric current (20 W for 1.5 – 2 hours, 4°C) 
was used to transfer proteins from the gel onto the PVDF or nitrocellulose 
membrane. Proteins were detected by immunocytochemistry (Table 2.6). 
 
2.14  Immunocytochemistry for protein detection  
 
Depending on the antibodies used for detection, the membrane was blocked for 1.5 
hours at room temperature in TBS/Tween (50 mM Tris/HCl pH 8, 150 mM NaCl, 2.5 
mM KCl, 0.1% Tween-20) containing either 5% milk powder (Töpfer, Dietmannsried) 
or 3% bovine serum albumin (Merck). Subsequently, the membrane was incubated 
with a specific antibody over night at 4°C (Table 2.6). After washing 3x with 
TBS/Tween, the membrane was incubated for 1 hour at room temperature with the 
adequate secondary antibody coupled with horseradish peroxidase. After 3x washing 
the membrane with TBS/Tween, specific proteins were detected by 
chemiluminenscence using ECL reagent (Amersham). 31 
 
Western blot  Company  Dilution  Blocking  Secondary 
antibody 
anti-Dicer Abcam  1/500  3% BSA  anti-mouse-HRP 
anti-Drosha Upstate  1/1000  5% Milk  anti-rabbit-HRP 
anti-TOPO I  Santa Cruz  1/250 5%  Milk  anti-rabbit-HRP 
anti-HSP70 Upstate  1/500  5% Milk  anti-rabbit-HRP 
anti-TSP Lab  Vision  1/250  3% BSA  anti-mouse-HRP 
anti-Integrin α5  Chemicon 1/500 3%  BSA anti-rabbit-HRP 
anti-SIRT1 Upstate  1/1000  5% Milk  anti-rabbit-HRP 
anti-eNOS BD  1/2500  3% BSA  anti-mouse-HRP 
anti-MKK4  Cell 
Signaling  1/1000 5%  Milk anti-rabbit-HRP 
Anti-AKT  Cell 
Signaling  1/1000 3%  BSA  anti-mouse-HRP 
Anti-P-AKT  Cell 
Signaling  1/1000 5%  Milk anti-rabbit-HRP 
anti-Tubulin Dianova  1/1500 3%  BSA  anti-mouse-HRP 
Immunostaining  Company  Dilution  Blocking  Secondary 
antibody 
anti-Dicer Abcam  1/50  2%  BSA  anti-mouse-544 
anti-Drosha Upstate  1/50  10%  FCS  anti-rabbit-546 
anti-Phospho-H3-
488 
Cell 
Signaling  1/10 0.2%  BSA  / 
SYTOX Blue  Invitrogen  1/1000  /  / 
Phalloidin-633 Invitrogen  1/300  /  / 
anti-SMA-Cy3 Sigma  1/300  1%  BSA  / 
anti-CD31-PE BD  1/100  1%  BSA  / 
Lectin 
(biotinylated)  Vector 1/50  1%  BSA  SAV Alexa 555 or 
488 
Lectin-FITC Sigma  0.2 mg in 
200 µl i.v. 
/ 
  / 
Anti-CD49e BD  1/25  2% Donkey 
serum  Anti-rat Alexa 594 
FACS  Company  Dilution  Blocking  Secondary 
antibody 
anti-CD49e-FITC Immunotech 1/10  1%  BSA  / 
 
 
Table 2.6 Antibodies for Western Blot and Immunostaining 32 
 
2.15 Immunofluorencence 
 
For detection of intracellular proteins, HUVEC were grown on a cover slip for 24 
hours. Cells were washed with phosphate buffer and fixed in 4% paraformaldehyde 
(PFA) for 15 min at room temperature and permeabilized with 0.25% Triton X-100. 
After blocking in 2% BSA for 30 min at room temperature, cover slips were incubated 
over night a 
t 4°C with the primary antibody. After washing 3x with phosphate buffer, cover slips 
were incubated for 1 hour at room temperature with the adequate secondary 
antibody.  
Cover slips were washed again incubated stepwise with antibodies for staining of 
cytoskeleton, nucleus and proliferation status. Proteins were detected by confocal 
microscopy. 
 
2.16  Stimulation with VEGF  
 
For stimulation with vascular endothelial growth factor (VEGF), HUVEC were grown 
until 70% confluence. 1 hour before stimulation medium was replaced by EBM 
containing 5% BSA. 20 ng/ml or 50 ng/ml human VEGF were added to the medium 
and RNA was isolated after 24 h and 48 h as described above. 
 
2.17  Stimulation with zVAD 
 
In order to inhibit apoptosis of HUVEC, cells were transfected and incubated over 
night with zVAD (100µM) or the solvent DMSO. The next day, cells were subjected to 
a spheroid assay as described above. 
2.18  Tube forming assay 
 
The vascular tube forming assay is a method to analyse the angiogenic potential of 
transfected cells in vitro. 48 h after transfection HUVEC (7x10
4) were cultured in a 
12-well plate (Greiner) coated with 200 μl Matrigel Basement Membrane Matrix (BD 33 
 
Biosciences). After several hours cells spontaneously form capillary-like structures. 
Tube length was quantified after 24 hours by measuring the cumulative tube length in 
five random microscopic fields with a computer-assisted microscope using the 
program KS300 3.0 (Zeiss). 
2.19  Spheroid-based angiogenesis assay 
 
The 3-D spheroid assay is another assay to investigate the angiogenic potential of 
endothelial cells. Endothelial cells are cultured over night in a viscous medium in 96-
well U-bottom shaped wells to allow the formation of spheroids. After collecting, the 
spheroids are embedded in a collagen-methocel gel, which polymerizes in a 24-well 
plate (Diehl et al., 2006; Korff and Augustin, 1998).
 Depending on the experimental 
outline 30 ng/ml bFGF were added to stimulate angiogenesis. Spheroids were 
quantified
 by measuring the cumulative length of the sprouts that had grown out of
 
each spheroid using a
  digital imaging software (Axioplan, Zeiss) analyzing
  10 
spheroids per experimental group and experiment.  
 
2.20  MTT viability assay 
 
Assessment of cell viability was performed using the [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide] MTT assay. 48 h after transfection 0.5 mg/ml MTT 
was added to each well and cells were incubated for 4 h at 37 C. Cells were washed 
with PBS and lysed 30 min at room temperature with lysis buffer (40 nM HCl in 
isopropanol). Absorbance was photometrically measured at 550 nm. 
 
 
2.21 Cell-matrix  adhesion 
 
Ninety-six-well plates were coated over night at 4 °C with 1 µg/mL soluble 
recombinant human collagen I (Roche, Mannheim, Germany) or 2.5 µg/mL human 
fibronectin (Roche, Mannheim, Germany) in PBS and then blocked for one hour at 
room temperature with
 3 % (w/v) heat-inactivated (2 h, 56 °C) human serum albumin 34 
 
(HSA). 48 h after transfection, HUVEC were stained with 2',7'-bis-(2-carboxyethyl)-5-
(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) or CellTracker Green 
(Molecular Probes,
  Eugene, Oregon) and after detachment with trypsin were 
resuspended in EBM with 0.05 % HSA. Then, cells were seeded at 50000 cells/well 
in 100 µL in the coated wells for 15, 30 and 45 min at 37 °C. After washing of non-
adhering cells with warm EBM, adherent cells were quantified
 in triplicates with a 
fluorescence plate reader (Fluostat, BMG Lab Technologies, Offenburg, Germany). 
 
2.22 Migration  assay 
 
To determine the migration of endothelial cells, HUVEC were detached with trypsin, 
harvested by centrifugation, resuspended in 500 μl EBM with 0.1% BSA, counted 
and placed in the upper chamber of a modified Boyden chamber (5x 10
4 cells per 
chamber, pore size 8 μm, BD Biosciences) coated with 2.5 µg/ml fibronectin. The 
chamber was placed in a 24-well culture dish containing EBM with 0.1% BSA in 
presence or absence of human vascular endothelial growth factor (VEGF, 50 ng/ml, 
Peprotech). After incubation for 5 h at 37°C, the non-migrating cells on the upper side 
of the chamber were mechanically removed and the remaining cells on the lower side 
were fixed with 4% formaldehyde. For quantification, cell nuclei were stained with 
4’,6-diamidino-phenylidole (DAPI). Migrating cells on the bottom side of the chamber 
were counted manually in five random microscopic fields. 
 
2.23  Cytokine and receptor array 
 
24 h after transfection, cells were starved for 20 h in EBM + 0.05% BSA. 
Supernatants were collected and concentrated 10-fold using Vivaspin columns. 10x 
supernatants were subjected to a human cytokine antibody array (Ray Bio) according 
to the instructions of the manufacturer. For the receptor array, cells were harvested 
48 h after the transfection, protein was isolated as described above and subjected to 
a receptor antibody array (Ray Bio) according to the manufacturer´s protocol.  
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2.24  Flow cytometry analysis 
 
For permeabilization, HUVEC transfected with pre92 or control were detached with 
trypsin, fixed in 4% formaldehyde for 10 minutes and treated with 0.1% TritonX-100.  
Cells (permeabilized and non-permeabilized) were blocked using 1% BSA and 
stained with Integrin α5 (Anti-CD49e-FITC 1:10, Immunotech) antibody. Cells were 
analyzed on a FACS Canto II device (BD). 
 
2.25 Proliferation  assay   
 
24 h after transfection, medium was changed and HUVEC were grown in the 
absence of serum (starving medium, EBM with 0.05% BSA) for 12 h. Cells were 
collected and stained with BrdU. FACS analysis was performed using a FACS Canto 
II device. 
 
2.26  Annexin V staining of cardiomyocytes 
 
Rat neonatal cardiomyocytes were pre-incubated with antagomir-92a for 48 h. Then, 
cells were washed and medium was replaced by medium without FCS („starving“) 
and antagomir-92a (150 nM) or PBS was added again for 24 h.  Apoptotic cells were 
detected by annexin V staining by FACS. 
 
 
 
 
2.27  Luciferase cloning and transfection 
 
Synthetic oligonucleotides bearing 4x the Integrin α5 binding sequence or a mutated 
sequence of miR-92a containing HindIII and SpeI restriction sites (Table 2.4) were 
cloned into firefly Luciferase reporter plasmid pMIR-Report (Ambion) according to the 
manufacturers protocol.  For measuring luciferase activity Hek293 cells were grown 36 
 
in 24-well plates until 60-70% confluence. 0.01 ng Luciferase plasmid was co-
transfected with 0.1 ng pGL4 Renilla plasmid (Promega) as control for the 
transfection efficiency and 30 pmol pre92 or control using Lipofectamine 2000 
(Invitrogen). The activity of Luciferase and Renilla was assessed after 24 h or 48 h 
with the Dual-Luciferase(R) Reporter 1000 Assay System (Promega). 
 
2.28 Plasmid  preparation 
 
Plasmid preparations were performed using commercially available kits for spin-, 
midi- or maxi preparation of plasmid DNA (Qiagen, Hilden). The concentration and 
purity of the DNA was determined photometrically. 
 
2.29  In vivo Matrigel plug assay with transfected HUVEC 
 
This assay was carried out as described previously (Potente et al., 2005) with the 
following modifications: HUVEC were transfected with pre92 or control as described 
above. 18 h after transfection, cells were labeled with cell tracker CM-Dil (Invitrogen), 
were detached, washed and counted. 1x10
6 cells were resuspended in 30 µl PBS 
and mixed with 500 µl Matrigel Basement
  Membrane Matrix (BD Biosciences) 
containing 15 units of heparin
 (Sigma-Aldrich). The cell-matrigel-mixture was injected 
subcutaneously into 6-8 wk old female athymic nude mice (Harlan) along the 
abdominal midline. After 6 days, invading cells in Matrigel
 plugs were quantified by 
analysis of H&E stained sections using microscopy. In order to analyse perfused 
capillaries, 200 µl FITC-conjugated lectin (1 mg/ml; Sigma) was injected i.v. 30 min 
before killing the mice. For hemoglobin analysis, the matrigel plug was removed after 
6 days and homogenized in 130 µl de-ionized water. After centrifugation, the 
supernatant was used in the Drabkin assay (Sigma-Aldrich) to measure hemoglobin 
concentration. Stock solutions of hemoglobin are used to generate a standard curve. 
Results are expressed relative to total protein in the supernatant. 
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2.30 Antagomirs   
 
The single-stranded RNA used in this study consisted of a 21–23-nucleotide length 
were synthesized by VBC Biotech, Vienna as previously described (Krutzfeldt et al., 
2005).  Antagomir sequences are listed in table 2.7. All animal models were 
maintained in a C57BL/6 background. Eight-week-old mice were injected 
subcutaneously with 2 matrigel basement matrix plugs at day 0 and received tail-vein 
injections of saline or antagomir-92a at day 1, 3 and 5. Antagomir-92a was 
administered at doses of 8 mg per kg body weight in 0.2 ml per injection. Tissue and 
matrigel plugs were harvested at day 6. Tissue was snap-frozen and stored in -80°C 
for RNA analysis. Hemoglobin, H&E staining and blood vessel infiltration were 
measured as described above. Additionally smooth muscle cells were stained using 
anti-SMA-Cy3 (Sigma). 
 
Antagomirs  Sequence  Company
Antagomir-92a CAGGCCGGGACAAGUGCAAUA  VBC  Biotech 
Antagomir-Co AAGGCAAGCUGACCCUGAAGUU VBC  Biotech 
Antagomir-Co 2  AAAUCCUUUAGACCGAGCGUGUGUU VBC  Biotech 
 
Table 2.7 Antagomirs 
2.31  In vivo matrigel experiments  
 
Eight-week-old mice were injected subcutaneously with 2 matrigel basement matrix 
plugs at day 0 and received tail-vein injections of saline, antagomir-Co or antagomir-
92a at day 1, 3 and 5. Antagomir-92a or antagomir-Co was administered at doses of 
8  mg  per  kg body weight in 0.2  ml per injection. Tissue and matrigel plugs were 
harvested at day 6. Capillaries were stained with anti-vWF and anti-rabbit Alexa 488 
(Invitrogen). In order to analyse perfused capillaries, 200 µl FITC-conjugated lectin (1 
mg/ml) was injected i.v. 30 min before harvest. Hemoglobin, H&E staining and blood 
vessel infiltration were measured as described above. Additionally, smooth muscle 
cells were stained using anti-SMA-Cy3 (Sigma). 
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2.32  Murine ischemic hind limb model 
 
The effect of antagomir-92a on ischemia-induced neovascularization was 
investigated in a murine model of hind limb ischemia using C57/Bl6 mice. 8 mg/kg bw 
antagomir-92a, antagomir-Co or PBS was injected at day 0, 2, 4, 7 and 9 after 
causing hind limb ischemia by ligation of the superficial and deep femoral artery and 
vein. Two weeks after induction of hind limb ischemia, the morphology of the limb 
was determined and blood flow ratio of the ischemic to normal limb was measured by 
using a laser Doppler blood flow meter (Laser Doppler Perfusion Imager System, 
moorLDI-Mark 2, Wilmington, DE). The perfusion of the ischemic and non-ischemic 
limb was calculated on the basis of colored histogram pixels. Red indicates high, blue 
indicates low perfusion. To minimize variables including ambient light and 
temperature and to maintain a constant body temperature, mice were exposed to 
infrared light for 10 min before laser Doppler scans. During the scan, mice were lying 
with their back on a heating pad with their legs stretched and fixed. The calculated 
perfusion was expressed as the ratio of ischemic to nonischemic hind limb perfusion. 
The necrosis of tips and toes was determined by the following rating: 0=none; 1=1-3 
tips; 2=4-5 tips; 3=1-3 toes; 4=4-5 toes; 5=1/3 foot; 6=2/3 foot; 8=whole foot; 10=1/3 
leg; 12=2/3 leg and 14=whole leg. For morphological analysis, 10-µm frozen sections 
of the muscle and semimembraneous muscles were used. Myocyte membranes were 
stained using anti-laminin (Abcam) followed by anti−rabbit-Alexa 488 (Molecular 
Probes) and anti-CD31-PE (BD). Arterioles were visualized using anti-SMA-Cy3 
(Sigma). For double staining, capillaries were visualized with biotinylated anti-lectin 
and SAV-Alexa 488 and arterioles by anti-SMA-Cy3 (Sigma). Integrin α5 was stained 
using anti-Integrin α5 (BD) and anti-rat Alexa 594 followed by anti-CD31-FITC (BD) 
to visualize capillaries. 
 
 
2.33  Induction of myocardial infarction and functional evaluation  
 
Myocardial infarction was induced by permanent ligation of the left coronary artery in 
10-12 week old C57/Bl6 mice.  Left coronary artery ligation was performed as 39 
 
described previously with modification (Patten et al., 1998). Mortality during or 
directly after operation was 22 %. After operation, mice were randomized in a blinded 
manner to the antagomir-92a, antagomir-Co or PBS group.  8 mg/kg bw antagomir 
92a, antagomir-Co or PBS was injected at day 0 (after operation), day 2, 4, 7 and 9 
after ligation of the coronary artery. In the PBS group n=2 mice died during the first 
week, in the antagomir-Co group n=1 mouse died, whereas no mouse died in the 
antagomir-92a group. On day 14, cardiac catheterization was performed for 
functional analysis by using 1.4F micromanometertipped conductance catheter 
(Millar Instruments Inc).  Left ventricular (LV) pressure and its derivative (LV dP/dt) 
were continuously monitored with a multiple recording system.  All data were 
acquired under stable hemodynamic conditions in a blinded manner. Functional 
difference between the groups were controlled in a second set of experiment by 
echocardiography (Vevo 770, VisualSonics, Toronto, Canada) showing an 
improvement of wall motion score index from day 0 to day 14 in the antagomir-92a 
group compared to antagomir-co. In order to analyze perfused capillaries, 200 µl 
FITC-conjugated lectin (1 mg/ml) was injected i.v. 30 min before harvesting the 
hearts. Morphological analysis after myocardial infarction was performed using 4-µm 
paraffin sections of the heart at day 14. Fibrosis was detected by Sirius Red staining. 
Therefore, sections were deparafinized and stained for 1h in 0.1% Picro Sirius Red 
(Sirius Red F3B in saturated aqueous solution of picric acid). Sections were washed 
2 times with acidified water, dehydrated using 100% ethanol and mounted in 
mounting medium (Dako). Arteries were visualized by smooth muscle actin staining. 
Apoptotic cells were detected in sections and cultured rat neonatal cardiomyocytes 
using  in situ cell death detection kit TMR-Red (Roche) according to the 
manufacturer´s protocol.  
 
 
 
2.34  Detection of miRNA and mRNA expression 
 
 To analyze the specificity and efficacy of Antagomir-92a, tissue was snap-frozen and 
stored at -80°C for RNA analysis. RNA isolation, cDNA synthesis and real time PCR 
were performed as described above. 40 
 
 
2.35  In situ hybridization  
 
To detect miR-92a expression, tissue was processed according to Obernosterer et 
al. (Obernosterer et al., 2007) and was stored at -80 °C. 10 µm sections were cut and 
thawed for 30 min at room temperature. After fixation with paraformadelyde (4%) for 
10 min, sections were washed 3 times for 5 min and incubated with protein kinase K 
(Sigma) for 5 min. After washing 3 times with PBS, sections were incubated with 
hybridization buffer for 4 h at room temperature. Meanwhile, probes (0.5 µl 3`-DIG 
labeled LNA probes, Exiqon) were mixed with 150 µl denaturation buffer, heated to 
80 °C for 5 min, chilled on ice and added to the sections followed by incubation over 
night at 56 °C. After incubation for 1 h in 50 % formamide / 1x SSC at 56 °C, 1h in 
0.2 SSC at 56 °C and 10 min in solution B1, sections were blocked for 1h at room 
temperature in blocking reagent. Then, anti-DIG AP (Roche) was added at a dilution 
of 1:500 for 1h at 37 °C. After washing with solution B1, sections were equilibrated in 
1 M Tris, pH=8.3 for 10 min at room temperature and subsequently incubated for 15 
min with Fast Red substrate (Dako) containing 1 drop levamisol. After washing in 
PBS/0.5% Tween-20, sections were mounted in DAPI mounting medium (Vector). 
 
2.36 TUNEL  staining 
 
MiR-92a was inhibited by injecting antagomir-92a (8 mg/kg bw, injected at days 0, 2, 
4, 7, 9) or antagomir-Co after ligation of left coronary artery. In order to quantify in 
vivo apoptosis after myocardial infarction TUNEL staining (in situ cell death detection 
kit, Roche) was performed using 4-µm paraffin sections of the heart at day 14.   
 
2.37  Affimetrix mRNA profiling 
 
HUVEC were transfected with pre92, control or siRNA for Integrin α5 and scrambled 
siRNA. Total RNA was isolated after 48 h, and the gene expression profile was 
assessed with the Affymetrix gene chip expression assay. 41 
 
 
2.38 Statistical  analysis 
 
Data are expressed as mean ± SEM. Two treatment groups were compared by 
Mann-Whitney test or student´s t-test, three or more treatment groups were 
compared by one-way analysis of variance followed by post-hoc analysis adjusted 
with a least significant difference correction for multiple comparisons (SPSS Inc.). 
Results were considered statistically significant when P < 0.05. 42 
 
3  Results 
 
MicroRNAs have been shown to play a crucial role in almost all biological processes. 
In order to study the general role of microRNAs in endothelial cells, we first analysed 
the expression and localization of the major microRNA-regulating enzymes Dicer and 
Drosha. Furthermore, the effect of siRNA, reducing the expression of Dicer and 
Drosha, on endothelial cell functions such as sprouting, viability and migration was 
analyzed. Since Dicer and Drosha are critically involved in microRNA biogenesis, we 
subsequently analysed microRNA expression after inhibition of Dicer and Drosha. In 
the second part of the thesis, we focused on the involvement of selected microRNAs 
on endothelial cell function such as proliferation, adhesion and their ability to improve 
recovery of ischemic tissues after hind limb ischemia or myocardial infarction in vivo.  
 
3.1  Expression and localization of Dicer and Drosha in endothelial 
cells 
 
Because the role of Dicer and Drosha in endothelial cells was unclear at the time 
when this study started, we first assessed the expression and localization of the two 
enzymes in endothelial cells using immunocytochemistry and confirmed these results 
by nuclear and cytoplasmic fractionation and subsequent western blot analysis.   A 
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Figure 3.1  Expression and localization of Dicer 
and Drosha in endothelial cells 
 (A)  Dicer and Drosha localization was assessed by 
immunocytochemistry. Dicer and Drosha  staining is 
shown in red fluorescence, phospho-H3 is used as 
proliferation marker (green), cytoskeleton is visualized by 
F-actin staining (blue) and nuclei (Sytox blue) are shown 
in white. B) Nuclear and cytoplasmic extracts were 
prepared as described in material and methods. Western 
blot analysis was performed using antibodies directed 
against Dicer, Drosha, Hsp70 and Topo I. 
B 
 
As shown for other cell types, Dicer is predominantly localized in the cytoplasm of 
endothelial cells, whereas the localization of Drosha is restricted to the nucleus (Fig. 
3.1 A/B). To determine whether Dicer and Drosha localization might be different in 
proliferating cells, we additionally identified proliferating cells by phospho-histone-H3 
staining. However, the proliferation status did not influence the localization of the two 
enzymes (Fig. 3.1 A/B). 3.2  Role of Dicer and Drosha for sprouting, tube formation and 
migration of endothelial cells  
 
In order to investigate the influence of Dicer and Drosha on the angiogenic potential, 
EC were transfected with siRNA targeting Dicer and Drosha compared to scrambled 
siRNA. We performed two different in vitro angiogenesis assays, the three-
dimensional spheroid assay and the two-dimensional matrigel vascular network 
formation assays.  To exclude an unspecific effect of the siRNAs, we tested the 
efficiency and specificity using two different siRNAs termed Dicer I/ Dicer II and 
Drosha I/ Drosha II (Fig. 3.2 A). PCR as well as western blotting demonstrate the 
specific suppression of Dicer and Drosha by the respective siRNA oligonucleotides 
(Fig. 3.2 B). Subsequent experiments were performed using Dicer I and Drosha I 
siRNA. 
siRNA. We performed two different in vitro angiogenesis assays, the three-
dimensional spheroid assay and the two-dimensional matrigel vascular network 
formation assays.  To exclude an unspecific effect of the siRNAs, we tested the 
efficiency and specificity using two different siRNAs termed Dicer I/ Dicer II and 
Drosha I/ Drosha II (Fig. 3.2 A). PCR as well as western blotting demonstrate the 
specific suppression of Dicer and Drosha by the respective siRNA oligonucleotides 
(Fig. 3.2 B). Subsequent experiments were performed using Dicer I and Drosha I 
siRNA. 
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Figure 3.2  siRNA mediated knockdown of Dicer and Drosha 
HUVEC were transfected with two different siRNAs targeting Dicer and Drosha, Dicer I and Dicer II 
as well as Drosha I and Drosha II or scrambled oligonucleotides. A) RT-PCR analysis of Dicer and 
Drosha mRNA expression after 24 h. A representative gel is shown. GAPDH served as loading 
control. B) 48 hours after transfection, cells were lysed and subjected to western blot analysis with 
antibodies against Dicer and Drosha. An antibody directed against tubulin was used as loading 
control. 
 
The reduction of Dicer and Drosha significantly inhibits basal and bFGF-stimulated 
endothelial cell sprout formation as measured by capillary sprouting in a three-
dimensional collagen-embedded spheroid culture assay (Fig. 3.3 A/B), while VEGF-
induced sprout formation is selectively blocked by Dicer siRNA (Fig. 3.3 C). Next, we 
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 tested whether the combined silencing of Dicer and Drosha further suppresses 
sprout formation. However, no additive effect was detected compared to the single 
reduction of Dicer or Drosha gene expression (Fig. 3.3 D/E).  
 
 
A 
B C 
D  E 
 
 
Figure 3.3 Dicer and Drosha regulate endothelial cell sprouting 
(A/B) HUVEC were transfected with Dicer and Drosha siRNA or scrambled oligonucleotides. A 
spheroid assay was performed to analyze basal or bFGF stimulated endothelial sprouting capacity. 
A) Representative spheroids are shown. B) Analysis of endothelial sprouting capacity with or without 
bFGF (30 ng/ml), n=3-4. C) Spheroids were stimulated with VEGF (50 ng/ml), n=4. D/E) HUVEC 
were transfected with Dicer and Drosha siRNA in combination. PCR and analysis of endothelial 
sprouting is shown. Endothelial sprouting capacity is given as cumulative sprout length per spheroid. 
Data are shown as mean±SEM (% scrambled without stimulation), n=4. 
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 To confirm the inhibitory effect of Dicer and Drosha knockdown assessed in the 
spheroid assay, we performed another in vitro angiogenesis assay detecting vascular 
network formation in matrigel. As shown in the spheroid model, suppression of Dicer 
and Drosha leads to a significant impairment of network forming activity (Fig. 3.4 
A/B). Since migration of endothelial cells is a key process during angiogenesis, we 
addressed the question, whether the reduction of Dicer and Drosha contributes to 
reduced endothelial cell migration. For that purpose, we performed a migration assay 
using a modified Boyden chamber. While Dicer siRNA-mediated knockdown 
significantly decreases the migratory capacity, Drosha knockdown has no effect on 
cell migration (Fig. 3.4 C).  
 
 
A B  C 
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Figure 3.4 Effect of Dicer and Drosha on tube formation, migration and cell viability 
(A-E) HUVEC were transfected with Dicer and Drosha siRNA or scrambled oligonucleotides. (A/B) 
HUVEC were seeded on a growth factor enriched Matrigel basement membrane matrix 24 hours 
after transfection. Representative micrographs and statistical summary of the tube forming activity, 
n=4. C) Cell migration was measured using a modified Boyden chamber. Cells were seeded in the 
upper chamber of a modified Boyden chamber 24 hours after transfection. Endothelial cell migration 
was assessed using VEGF (50 ng/ml) as chemoattractant, n=3 (D/E) Cell viability was measured 
using a MTT viability assay after 24 h (D) or 48 h (E), n=3.  
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 To test whether the reduction of endothelial cell sprouting and tube formation is 
secondary to a nonspecific effect on cell growth or apoptosis, we analysed cell 
viability using a MTT assay. As shown in Figure 3.4 D, Dicer and Drosha knockdown 
does not impair cell viability after 24 h. After 48 h, Dicer siRNA transfection slightly 
reduces viability, whereas Drosha siRNA transfection does not affect viability (Fig. 
3.4 E). In order to additionally investigate whether an induction of apoptosis mediates 
the anti-angiogenic effect of Dicer siRNA, apoptosis was blocked by the addition of 
the caspase-inhibitor zVAD. However, the reduced sprout forming activity of Dicer 
siRNA-transfected endothelial cells was not improved by zVAD addition (Fig. 3.5) 
indicating that the inhibition of sprout formation is independent of the induction of cell 
death.  
 
Figure 3.5 The anti-angiogenic 
effect of Dicer does not depend to 
induction of cell apoptosis 
HUVEC were transfected with Dicer 
siRNA or scrambled oligonucleotides. 
After medium change cells were 
stimulated with 100 µM zVAD or DMSO 
as control. 24 h after stimulation a 
spheroid assay under bFGF (30 ng/ml) 
stimulation was performed to analyze 
endothelial sprouting capacity, n=3. 
3.3  Dicer is required for in vivo angiogenesis 
 
Having shown that Dicer and Drosha contribute to in vitro angiogenesis, we further 
investigated the role of Dicer and Drosha on in vivo angiogenesis. Because Dicer-
deficient mice are embryonic lethal and Drosha-deficient mice were not available for 
the study, we subcutaneously injected matrigel plugs mixed with siRNA-transfected 
HUVEC into nude mice and assessed the sprout formation.  
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Figure 3.6 Dicer is required for in vivo angiogenesis 
HUVEC were transfected with Dicer and Drosha siRNA or scrambled. 18 h after transfection cells 
were labelled with CM-DiI and mixed in matrigel basement membrane. The matrigel-cell mixture 
was injected subcutanously in nude mice and plugs were harvested after 7 days. The number of 
invading cells was quantified by staining lectin or CD31 (A) and perfusion of matrigel plugs was 
analysed by measuring  the hemoglobin content (B), n=3-6. 
 
Vessel-like structures are significantly reduced in matrigel plugs with Dicer siRNA 
transfected HUVEC (Fig. 3.6 A). Silencing of Dicer additionally reduces matrigel plug 
hemoglobin concentrations indicating that the blood supply is reduced (Fig. 3.6 B). In 
contrast, Drosha siRNA transfection does not significantly affect sprouting 
angiogenesis and hemoglobin concentration of matrigel plugs in vivo (Fig. 3.6 A/B). 
In summary, our data provide evidence that Dicer and Drosha are critically involved 
in angiogenic processes in vitro and in vivo. 
 
3.4 microRNAs  enriched  in endothelial cells 
 
In order to detect microRNAs, which are highly enriched in EC, we performed a 
microRNA profiling. Since the high throughput expression profiling of microRNAs was 
still in its fancies at the beginning of the study, we performed two different profilings 
based on different methods. As shown in Fig. 3.7 A the expression of about 360 
microRNAs in HUVEC was analysed using quantitative real-time PCR. In this 
approach, during reverse transcription the microRNA is elongated by a specific stem 
loop primer and subsequently subjected to real-time PCR using specific primer and 
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 Taqman probes. In a second approach, 344 microRNAs expressed in HUVEC were 
quantified using microRNA microarray analysis (Fig. 3.7 B).      
 
 
 
 
A) The expression of 360 human microRNAs was profiled using real-time PCR. Comparative 
analysis was performed for 23 microRNAs, detected in all three samples. Raw data were 
normalized to RNU48 and converted using the formula 2
-∆Ct  (relative expression). Data are 
mean±SEM, n=3. B) The expression analysis of 344 human microRNAs was performed from total 
RNA using miRCURY LNA arrays. Representative analysis is shown for 16 microRNAs, n=1. 
Figure 3.7 microRNA expression profile in HUVEC 
Selected miRNAs highly expressed in both assays are summarized in Fig. 3.7. 
Recent studies demonstrate that some of these highly expressed miRNAs play a 
major role in vascular biology. MiR-221 and miR-222 target the stem cell factor ligand 
c-kit, thereby changing the angiogenic properties of HUVEC (Poliseno et al., 2006). 
Furthermore, two current studies in zebrafish and mouse models show that miR-126 
stimulates angiogenesis in vitro and in vivo by targeting the negative regulator of 
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Ras/MAP signaling, SPRED1 (Fish et al., 2008; Wang et al., 2008). Interestingly, the 
whole miR-17-92 cluster encoding the miRNAs miR-17-5p, miR-17-3p, miR-18a, 
miR-19a, miR-20a, miR-19b and miR-92-a-1 is highly expressed in HUVEC,  and 
particularly miR-92a, whose specific role in angiogenesis has not been investigated 
before. In contrast, the homologues miR-106a-363 cluster on the X-chromosome 
encoding miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92-a-2 and miR-363 seems 
not to be processed in endothelial cells (Fig. 3.7 A).  
 
3.5  Dicer and Drosha regulate the expression of miRNAs in 
endothelial cells 
 
Since Dicer and Drosha are the major enzymes of microRNA biogenesis, we 
hypothesized that the observed defects on in vitro angiogenesis shown after 
knockdown of Dicer and Drosha described above might be due to the reduced 
expression of microRNAs. To identify microRNAs, which might be responsible for the 
functional defects, we analyzed the expression of 344 human miRNAs after siRNA-
mediated knockdown of Dicer and Drosha using a microRNA array (Table 3.1 and 
Fig. 3.7 B). The expression of 202 miRNAs was below the detection limit of the 
assay. Unexpectably, the selective analysis of the effect of Dicer and Drosha 
downregulation revealed that the expression of only two miRNAs is reduced to more 
than 30% by Dicer knockdown, while 29 miRNAs are reduced to more than 30% by 
Drosha knockdown, 31 miRNAs are regulated by both enzymes (Fig. 3.8). To identify 
microRNAs, which might be responsible for the functional defects, we analyzed the 
expression of 344 human miRNAs after siRNA-mediated knockdown of Dicer and 
Drosha using a microRNA array (Table 3.1 and Fig. 3.7 B). The expression of 202 
miRNAs was below the detection limit of the assay. 
 
 
 
 
 
 
 miRNA 
siRNA Dicer 
(%vs. scr) 
siRNA Drosha 
(%vs. scr) 
hsa-let-7a 64 56 
hsa-let-7b 62 60 
hsa-let-7c 63 56 
hsa-let-7d 71 60 
hsa-let-7f 59  52 
hsa-let-7g 71 57 
hsa-miR-10b 68  56 
hsa-miR-126 83  54 
hsa-miR-17-5p 73  60 
hsa-miR-193a 67  42 
hsa-miR-21 98  50 
hsa-miR-22 73  45 
hsa-miR-221 66  54 
hsa-miR-23a 90  56 
hsa-miR-24 87  64 
hsa-miR-26a 93  53 
hsa-miR-27b 64 
below 
detection 
hsa-miR-29a 82  58 
hsa-miR-30c 72  56 
hsa-miR-331 42  34 
hsa-miR-365 81  60 
hsa-miR-486 163  62 
 
Table 3.1 microRNA expression profile after Dicer and Drosha  
suppression 
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Unexpectably, the selective analysis of the effect of Dicer and Drosha 
downregulation revealed that the expression of only two miRNAs is reduced to more 
than 30% by Dicer knockdown, while 29 miRNAs are reduced to more than 30% by 
Drosha knockdown, 31 miRNAs are regulated by both enzymes (Fig. 3.8). These 
results are very suprising, since Dicer acts downstream of Drosha, therefore its inhibition should have a similar effect on microRNA expression as the knockdown of 
Drosha.  
 
 
 
 
 
Figure 3.8 microRNA expression profile after Dicer and Drosha 
suppression 
 
In order to confirm these data, we selected some highly downregulated miRNAs, 
miR-27b and let-7f, and performed RT-PCR. Indeed, both miRNAs were profoundly 
reduced after Dicer and Drosha knockdown as presented in Fig. 3.9 A/B. Based on 
the fact that miR-27b and let-7f potentially target the endogenous angiogenesis 
inhibitors Semaphorin 6a (Dhanabal et al., 2005) and thrombospondin-1 (only let-7f) 
(Iruela-Arispe et al., 1991), we further tested the functional effect of mir-27b and let-7f 
inhibition in endothelial cells. For that purpose, the miRNAs were blocked by specific 
inhibitors, so-called 2`O-methyl antisense oligoribonucleotides and transfected EC 
were subjected to a spheroid assay.  As shown in Fig. 3.9 C, inhibition of miR-27b as 
well as let-7f significantly reduces in vitro sprout formation to the same extend 
suggesting that these miRNAs are indeed pro-angiogenic by targeting anti-
angiogenic genes. 
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Figure 3.9 microRNA expression profile after Dicer and Drosha suppression 
(A/B) HUVEC were transfected with Dicer and Drosha siRNA or scrambled oligonucleotides. The 
expression of miR-27b and let-7f was analyzed 48 h after transfection using RT-PCR. A)  A 
representative gel is shown. The small nuclear ribonucleoprotein U6 serves as loading control. B) 
Quantitative analysis, n=5. C) Spheroid sprouts were detected 72 h after transfection with 2´O-
methyl antisense oligoribonucleotides against miR-27b and let-7f, n=4. Representative spheroids 
are shown.   
 
3.6  Dicer and Drosha silencing induces the upregulation of 
thrombospondin-1 expression 
 
Next, we assessed the expression of thrombospondin-1 (TSP1) after Dicer and 
Drosha siRNA transfection. As shown in Fig. 3.10 A, the reduction of Dicer and 
Drosha by siRNA transfection significantly increases the expression of TSP1 to 263 ± 
68% in Dicer siRNA-transfected cells and to 358 ± 95% in Drosha siRNA-transfected 
cells, respectively.  
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Figure 3.10 Dicer and Drosha regulate the expression of Thrombospondin-1 
A) HUVEC were transfected with Dicer and Drosha siRNA or scrambled oligonucleotides. 48 hours 
after transfection, cells were lysed and subjected to western blot analysis with an antibody targeting 
thrombospondin-1. An antibody against tubulin was used as loading control. A representative 
western blot and quantitative analysis are shown, n=6. B) HUVEC were transfected with Dicer, 
Drosha and / or TSP1 siRNA or scrambled oligonucleotides. 18 hours after transfection, cells were 
lysed and subjected to western blot analysis with an antibody against thrombospondin-1. An 
antibody against tubulin was used as loading control. The angiogenic potential of transfected cells 
was analysed 72 h after transfection in response to bFGF stimulation using a spheroid model, n=3. 
 
 
Based on the hypothesis, that the reduction in capillary sprout formation after Dicer 
and Drosha knockdown might be mediated by an increase of TSP1 expression, we 
simultaneously transfected HUVEC with Dicer or Drosha siRNA and siRNA targeting 
TSP1.  However, simultaneous transfection of siRNA targeting TSP1 and Dicer or 
Drosha does not rescue the impaired sprout formation induced by Dicer or Drosha 
deficiency (Fig. 3.10 B) indicating that additional targets contribute to the Dicer and 
Drosha siRNA-mediated angiogenesis inhibition.  
Since let-7f in comparison to other let-7 family members is most profoundly 
downregulated by Dicer and Drosha, we additionally investigated the effect of a let-7f 
inhibitor on TSP1 expression. However, inhibition of let-7f induces only a minor, not 
significant increase in TSP1 expression to 115 ± 18% (data not shown) suggesting 
that additional miRNAs are involved in the regulation of TSP1. 
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 3.7  Effect of Dicer and Drosha silencing on cytokine expression 
and AKT signaling  
 
Since the profound sprouting defect mediated by Dicer and Drosha siRNA was not 
explainable by the dysregulation of single genes, we elucidated the effect of Dicer 
and Drosha on the expression of several angiogenic growth factors and receptors by 
using a human receptor and cytokine array.  
 
A 
B 
 
Figure 3.11 Effect of Dicer and Drosha silencing on cytokine and receptor 
expression 
HUVEC were transfected with siRNA against Dicer and Drosha or scrambled oligonucleotides. A) 
48 h after transfection cells were lysed and subjected to human receptor antibody array (Ray Bio). 
Quantitative analysis of receptor expression is shown, n=3. B) 24 h after transfection, cells were 
starved for 20 h in EBM + 0.05 % BSA. 10x supernatants were subjected to a human cytokine 
antibody array (Ray Bio), n=3. Quantitative analysis of cytokine expression is shown.   
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Although Dicer siRNA significantly suppresses angiogenesis, the expression of most 
of the pro-angiogenic receptors is not influenced in Dicer-silenced endothelial cells. In contrast, Drosha knockdown enhances expression of some selected receptors 
important for endothelial function, such as VE-Cadherin, TIE2 and TIE1 (Fig. 3.11 A). 
On the other hand, suppression of Dicer leads to increased expression of pro-
angiogenic cytokines like Angiopoetin-2, and DKK4, which could not be observed in 
Drosha siRNA transfected HUVEC (Fig. 3.11 B).  
VEGF is an important pro-angiogenic factor, which activates the serine/threonine 
kinase AKT by binding to its receptor KDR. AKT has been shown to play a critical 
role in angiogenesis signaling, especially in proliferation, apoptosis inhibition and 
migration of endothelial cells (Dimmeler and Zeiher, 2000). In order to study the role 
of Dicer and Drosha in AKT signaling, we analysed the expression of the KDR and 
AKT-P in greater detail using Western blot analysis. However, no significant 
difference in KDR expression was detected after Dicer and Drosha inhibition (Fig. 
3.12 A). However, the phosphorylation of AKT is selectively inhibited in Dicer siRNA 
compared to Drosha siRNA treated cells (Fig. 3.12 B) indicating an interference of 
Dicer with AKT activation. 
 
 
A B 
 
Figure 3.12.Dicer is involved in AKT signaling 
HUVEC were transfected with siRNA against Dicer and Drosha or scrambled oligonucleotides. A) 
KDR expression was assessed by FACS staining. Quantitative analysis is shown, n=3. B) To 
assess AKT phosphorylation, cells were lysed and subjected to western blot analysis using an 
antibody against phospho-AKT. Total AKT was used as loading control, n=3. Quantitative analysis 
is shown.  
 
 
In summary, the presented data shows that Dicer is critically involved in 
angiogenesis in vitro as well as in vivo by blocking expression of several microRNAs 
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and thereby inhibiting migration and cell viability. Furthermore, Dicer interferes with 
the AKT signaling pathway, which has been shown to play a crucial role in 
angiogenesis. In contrast, silencing of Drosha also inhibits in vitro angiogenesis, but 
has no effect on in vivo angiogenesis, migration and cell viability. Surprisingly, 
downregulation of Drosha more profoundly influenced the expression of several 
microRNAs compared to Dicer despite the fact that Dicer more efficiently contributes 
to angiogenesis.  3.8 Regulation  of  in vitro angiogenesis by highly expressed 
miRNAs  
 
In the second part of this thesis, we focused on the relevance of specific microRNAs 
for endothelial cell biology. As shown in Fig. 3.7, we identified individual microRNAs 
highly expressed in HUVEC. In order to investigate the contribution of microRNAs to 
in vitro angiogenesis, we used 2`O-methyl antisense oligoribonucleotides for 
inhibition of some of the highly expressed microRNAs and performed a spheroid 
assay (Fig. 3.13). The inhibition of miR-92a, miR-191 and miR-214 enhances 
capillary sprouting under basal conditions (Fig. 3.13 A) suggesting that these 
microRNAs might act anti-angiogenic. However, only a minor increase in sprouting 
was detected after stimulation with bFGF (Fig. 3.13 B). 
 
 
Figure 3.13 Role of highly expressed microRNAs in in vitro angiogenesis 
HUVEC were transfected with 2`O-methyl antisense oligoribonucleotides inhibiting microRNA 
expression. A spheroid assay was performed to analyze basal (A) and bFGF –stimulated (B) 
endothelial sprouting capacity. The cumulative sprout length of each spheroid was measured after 
24 h in the collagen matrix, n=3.     
 
 
MiR-92a is a member of the miR-17-92 cluster, which has been previously reported 
to be involved in tumorangiogenesis by targeting the anti-angiogenic protein TSP1 
(Thrombospondin 1) and CTGF (Connective tissue growth factor) (Dews et al., 2006). 
However, the specific role of miR-92a in angiogenesis has not been studied so far. 
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Therefore, we investigated the effect of inhibition and overexpression of miR-92a in 
vitro on endothelial functionality and inhibited miR-92a in vivo to analyse the 
contribution to the recovery after ischemia in a hind limb ischemia and myocardial 
infarction model. 
 
3.9 miR-92a  impairs  in vitro and in vivo angiogenesis 
 
Overexpression of miR-92a using specific precursor molecules (termed pre92) in 
HUVEC results in >2-fold increase in the levels of miR-92a compared to control 
precursor (Fig. 3.14 A). In contrast to recent publications, which show that the miR-
17-92 cluster has pro-angiogenic functions mainly exerted by miR-18a and miR-19a, 
miR-92a overexpression in endothelial cells unexpectedly blocks sprout formation in 
a three-dimensional model of in vitro angiogenesis (Fig. 3.14 B). 
These results were confirmed by a second in vitro angiogenesis model, the vascular 
network formation in matrigel (Fig. 3.14 C). Representative images of the spheroid 
model and vascular network formation assay are shown in Fig. 3.14 D. 
Migration and adhesion as well as apoptosis and proliferation of endothelial cells are 
key process during angiogenesis. Therefore, we addressed the question, whether the 
overexpression of miR-92a might contribute to these processes. Overexpression of 
miR-92a reduces EC adhesion to fibronectin after 15 min and 30 min (Fig. 3.14 E). 
Additionally, basal and VEGF-induced endothelial cell (EC) migration measured in a 
modified Boyden chamber is impaired (Fig. 3.14 F). In order to exclude a cytotoxic 
effect of miR-92a overexpression, we additionally analysed proliferation and viability 
of transfected cells. However, overexpression of miR-92a does not affect EC viability 
or proliferation under basal conditions or after serum depletion (Fig. 3.14 G/H). In an 
attempt to investigate the role of miR-92a overexpression in vivo, HUVEC transfected 
with pre92 or a control precursor were first stained with CM-DIL in order to 
discriminate later between the implanted HUVEC cells and the invaded host cells. 
 
  
Figure 3.14 Overexpression of miR-92a impairs angiogenesis in vitro 
HUVEC were transfected with a miR-92a precursor (pre92) or a control precursor. A) Expression of 
miR-92 in pre-miR-92a (pre92) transfected endothelial cells. B) A 3D spheroid assay was performed 
24 h after transfection. The cumulative sprout length of each spheroid was measured after 24 h in the 
collagen matrix, n=3. C) Matrigel tube formation of transfected HUVEC was assessed after 48 h, n=3. 
D) Representative images of spheroid and matrigel assays are shown. E) Effect of pre92 on adhesion 
to fibronectin. Adhesion was measured with a fluorescence plate reader after 15 min and 30 min, n=4. 
F) Migratory capacity of pre92 transfected HUVEC was analysed using the modified Boyden chamber 
coated with fibronectin. Transmigrated HUVEC were stained after 5 h with DAPI and counted in 5 
random high power fields, n=3. G) MTT viability assay was performed 48 h after transfection to 
exclude toxicity, n=4. H) 24 h after transfection, medium was changed and cells were grown in the 
absence of serum (starving medium, EBM with 0.05 % BSA)  for 12 h. Cells were collected and 
stained with BrdU. FACS analysis was performed using a FACS Canto II device, n=3. 
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In a further attempt, HUVEC were mixed with matrigel and subcutaneously injected in 
nude mice. After 6 days, the overall number of invading cells is significantly 
decreased in matrigel plugs containing pre92 transfected HUVEC compared to 
control as shown in H&E staining (Fig. 3.15 A). Whereas control transfected HUVEC 
form vessel-like structures together with host-derived as shown by staining with von 
Willebrand factor (green), no host-derived cells were detectable in matrigel plugs 
containing pre92-transfected HUVEC (Fig. 3.15 B). In order to additionally quantifiy 
the number of perfused vessels, we infused FITC-conjugated lectin 30 min before 
explantation of the matrigel plugs. Matrigel plugs implanted with pre92-transfected 
HUVEC demonstrate a significantly lowered number of in vivo lectin-perfused vessels 
and impaired perfusion as determined by measuring the hemoglobin concentrations 
(Fig. 3.15 C/D). These results indicate that overexpression of miR-92a blocks 
angiogenesis in vitro and in vivo.  
 
Figure 3.15 Overexpression of miR-92a impairs angiogenesis in vivo 
HUVEC were transfected with pre92 or control oligonucleotides. 1 x 10
6 cells were stained with CM-DIL, 
mixed in matrigel and subcutaneously implanted in vivo. After 6 days, matrigel plugs were explanted 
and invading cells were detected in H&E sections (A) and after immunostaining with vWF antibody 
(green). CM-Dil labelled implanted HUVEC are red, Nuclei are stained with DAPI (blue), n=5-6 (B). In 
vivo perfused lectin-positive vessels were identified and counted after i.v. infusion of FITC-conjugated 
lectin, n=8 high power fields (C). Perfusion was determined by measuring the hemoglobin content, n=6-
7 (D). 
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 3.10  Inhibition of miR-92a enhances angiogenesis and 
neovascularization in vitro and in vivo  
 
Next, we investigated whether inhibition of miR-92a might be useful to enhance 
vessel growth. As shown in Fig. 3.13 and Fig. 3.16, inhibition of endothelial miR-92a 
by 2`O-methyl antisense oligonucleotides increases sprout formation in vitro.  
 
 
Figure 3.16 Inhibition of miR-92a 
enhances angiogenesis in vitro 
miR-92a expression and sprout formation in 
HUVEC after transfection with 2`O-methyl 
antisense oligoribonucleotides blocking miR-92a, 
n=4. 
 
To inhibit miR-92a in vivo, we designed single-stranded RNA oligonucleotides 
complementary to specific miRNAs, also known as antagomirs. Antagomirs are 
chemically modified for improved stability by substitution of 2 phosphothioates at the 
5`end and 4 phosphothioates at the 3`end. In addition, each nucleotide is conjugated 
with a 2`O-methyl group for stronger binding of the miRNA and cholesterol is added 
to the 3`end for increased cell delivery (Krutzfeldt et al., 2005) (Fig. 3.17). 
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Figure 3.17 Antagomirs 
Antagomirs are single-stranded RNA 
oligonucleotides complementary to 
specific miRNAs. They are chemically 
modified for stability and cholesterol 
conjugated for better delivery (Krutzfeld 
et al., Nature 2006) 
First, we analysed the uptake of antagomirs in different tissues and elucidated the 
antagomir concentration inducing a sufficient knockdown of miR-92a in vivo.   
 
Figure 3.18 Dose-dependent downregulation of miR-92a by antagomir-92a 
A) 48 h after i.v. infusion of Cy3-labelled antagomir-92a at concentrations of 1 mg/kg bw, 8 mg/kg 
bw and 40 mg/kg bw heart, spleen, and liver were harvested. The uptake of Cy3-labelled 
antagomir-92a was analysed in histological sections, capillaries were stained with Lectin. B) At day 
1 after injection of Cy3-labelled antagomir-92a, skeletal muscle tissue was harvested and Cy3-
labelled antagomirs were detected by confocal microscop in frozen 10-µm sections. Cy3-labelled 
antagomir-92a is shown in red, in vitro counterstaining with lectin is shown in green. Nuclei are 
stained with DAPI (blue). C)  RNA of different tissues was isolated 48 h after infusion of Cy3-
labelled antagomir-92a by Trizol. Quantitative analysis of miR-92a expression was performed by 
real-time PCR, n=1-2.  
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Therefore, we i.v. injected antagomirs targeting miR-92a (from hereon antagomir-
92a) carrying a Cy3 label at the 5`end at concentrations of 1mg/kg, 8mg/kg and 40 
mg/kg and analysed the biodistribution in heart, spleen, muscle and liver two days 
after injection.  Whereas 1mg/kg Cy3-labelled antagomir-92a was not detectable in any tissue, we 
observed antagomir-92a in all tissues already at the relatively low concentration of 
8 mg/kg (Fig. 3.18 A/B). Additionally, we isolated RNA from the different tissues 2 
days after i.v. injection of Cy3-labelled antagomir-92a and analysed miR-92a 
expression using real-time PCR. As shown in Fig. 3.18 C, 1mg/kg antagomir-92a 
decreases miR-92a expression only to a minor extent in heart, spleen and muscle, 
whereas a significant knockdown is achieved in the liver. 8 mg/kg as well as 40 
mg/kg antagomir-92a sufficiently blocks miR-92a expression in all analysed tissues.  
High resolution images of heart sections from mice treated with 8 mg/kg Cy3-labelled 
antagomir-92a and co-staining of perfused capillaries by injection of Lectin-FITC 
show that antagomir-92a is preferentially taken-up by vascular cells of the heart (Fig. 
3.19) at the rather low concentration of 8 mg/kg bw used in the present study. 
 
 
Figure 3.19 Antagomir uptake in the heart 
24 h after i.v. infusion of Cy3-labelled antagomir-92a (8mg/kg 
bw) hearts were harvested. Perfused capillaries are stained by 
i.v. injection of Lectin-FITC, Nuclei were stained with DAPI 
(blue). Cy3-labelled antagomir-92a is shown in red.  
 
 
Since we showed that a concentration of 8 mg/kg antagomir-92a sufficiently blocks 
miR-92a expression in different tissues (Fig. 3.18) one day after a single injection 
and is targeting mainly the vasculature (Fig. 3.19), we analysed the efficiency after 
repetitive treatment. Systemic application of 8 mg/kg antagomir-92a at day 1, 3 and 5 
after implantation of matrigel plugs efficiently inhibits miR-92a expression in tissues 
like heart, spleen and liver harvested at day 6 (Fig. 3.20). 
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Figure 3.20 Inhibition of miR-92a expression in different tissues 
Antagomir-92a or antagomir-Co were injected at day 1, 3, and 5. At day 6 different tissues were 
harvested and miR-92a expression was analysed in heart (A), spleen (B) and liver (C) using real-
time PCR, n=3-5. MiR-92a expression was normalized to miR-24. 
 
 
Having shown that repetitive antagomir-92a treatment efficiently blocks miR-92a 
expression in different tissues, we further analysed the effect of miR-92a inhibition on 
plug vascularization. Consistent with the hypothesis that inhibition of miR-92a 
augments angiogenesis, systemic application of antagomirs enhances the number of 
invading cells shown in a H&E staining (Fig. 3.21 A/B). Furthermore, the number of in 
vivo perfused lectin-positive vessels in implanted matrigel plugs (Fig. 3.21 C) and the 
hemoglobin content as a parameter for perfusion is significantly increased 
(Fig. 3.21 D).  
To control for off-target effects of single-stranded RNA oligonucleotides and to 
confirm the specificity of antagomir-92a, we used two different control antagomirs, 
which both did not affect plug vascularization (Fig. 3.21 A).  
These data clearly demonstrate a pro-angiogenic function of antagomir-92a in vivo. 
Antagomir-92a represses miR-92a expression in vivo, thereby promoting 
vascularization in matrigel plugs.  
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Figure 3.21 Inhibiton of miR-92a enhances angiogenesis in vivo   
Effect of systemic infusion of antagomirs targeting miR-92a (8 mg/kg bw, n=12), two different control 
antagomirs (Antagomir-Co and antagomir-Co2, each n=5-8) or PBS (n=11) at day 1, 3, 5. The 
number of invading cells was counted in H&E sections (A/B). Number of lectin-positive vessels was 
assessed by injection of FITC-conjugated lectin (C) and perfusion was measured by hemoglobin 
content (D). *p<0.05 compared to PBS, 
#p<0.05 compared to antagomir-Co for all panels. 
 
3.11  MiR-92a is regulated by ischemic injury 
 
We further addressed the question, whether antagomir-92a might be an attractive 
therapeutical tool to promote angiogenesis in ischemic diseases.   
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Therefore, we first determined the time-dependent expression of miR-92a in 
response to ischemia in two different models of ischemia, a model of hind limb 
ischemia and a myocardial infarction model (Fig. 3.22). RNA from the ischemic hind 
limb was isolated at the indicated time points and miR-92a as well as miR-92b and 
miR-93 expression was quantified using real-time PCR. Ischemic injury significantly increases miR-92a expression with a maximal effect between 1-3 days (Fig. 3.22 A), 
suggesting a pathophysiological role for miR-92a in vivo. In accordance with the hind 
limb ischemia data, we could observe a significant increase in miR-92a expression in 
the infarcted vs. non-infarcted region one day after ligation of the left coronary artery. 
 
Figure 3.22 miR-92a is upregulated by ischemia    
A) Expression of miR-92a, miR-92b, miR-18a and miR-93 was detected in ischemic muscle tissue 
at the respective days compared to non-ischemic control muscle. n=3. B) Day 1 after ligation of left 
coronary arteria, hearts were divided for infarcted and non-infarcted parts. Expression of miR-92a in 
infarcted vs. non infarcted region was analysed using real-time PCR, n= 4-5. *p<0.05 compared to 
PBS, 
§p<0.05 compared to non-ischemic control muscle. HLI operation was performed by Ariane 
Fischer. AMI operation was performed by Henrik Fox. 
 
 
To test the efficiency and specificity of antagomir-92a treatment under ischemic 
conditions, we determined the expression of miR-92a and the closely related miR-
92b, which differs only in 2 nucleotides, under ischemic conditions and simultaneous 
treatment with antagomir-92a. Additionally, we analysed expression of other 
members of the miR-17~92 cluster, namely miR-18a and miR-19a, and the unrelated 
miR-93 in ischemic and non-ischemic muscle. Whereas one single injection of 
antagomir-92a significantly suppresses miR-92a expression in non-ischemic and 
ischemic limbs, miR-92b is only slightly and non-significantly reduced. Moreover, 
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 none of the other miRNAs studied is suppressed by antagomir-92a treatment (Fig. 
3.23 A). Likewise, a specific and efficient knockdown of miR-92a by antagomir-92a 
treatment was demonstrated also in the heart (Fig. 3.23 B).  
 
 
Figure 3.23 miR-92a is specifically downregulated by antagomir-92a    
A) Antagomir-92a (8 mg/kg bw, i.v. injected once directly after induction of ischemia) specifically 
reduces miR-92a expression in ischemic and non-ischemic muscle tissue 2 days after induction of 
hind limb ischemia. Expression of miRs was determined by real time PCR as indicated in antagomir-
92a or control antagomir-treated mice and was compared to non-treated controls, n=4. B) miR-92a 
expression in hearts 6 days after antagomir-92a treatment compared to control antagomirs, n=3-8. 
miR-24 expression was detected as control.  
 
 
3.12 Antagomir-92a improves functional recovery after hind limb 
ischemia 
 
We have shown that miR-92a is upregulated by ischemia and specifically 
downregulated by antagomir-92a. Furthermore, inhibition of miR-92a improves 
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 vessel formation in matrigel plugs. Therefore, we tested whether antagomir-92a 
promotes blood vessel growth and improves functional recovery in vivo under 
pathophysiological conditions using a model of hind limb ischemia.  
 
Figure 3.24 Antagomir-92a improves recovery after hind limb ischemia 
Antagomir-92a, control antagomir (Antagomir-Co) (8 mg/kg bw) or PBS was injected at days 0, 2, 4, 
7, 9 after induction of hind limb ischemia. A) At day 14, necrosis of tips and toes was determined by 
the following rating: 0=none; 1=1-3 tips; 2=4-5 tips; 3=1-3 toes; 4=4-5 toes; 5=1/3 foot; 6=2/3 foot; 
8=whole foot; 10=1/3 leg; 12=2/3 leg and 14=whole leg, n=5.  B) Blood flow ratio of the ischemic to 
normal limb was measured by using a laser Doppler blood flow meter at day 14, n=5 C/D) Muscle 
tissue was harvested at day 14 and stained with smooth muscle actin (red) and lectin in vitro 
(green).  C) Quantitative analysis of smooth muscle actin-positive vessels (50-100 µm) and (D) 
representative images, n=4. HLI operation was performed by Ariane Fischer. 
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Intravenous infusion of antagomir-92a at day 0, 2, 4, 7 and 9 leads to a significant 
reduction in toe necrosis compared to antagomir-Co and PBS-treated control mice 14 
days after induction of hind limb ischemia (Fig. 3.24 A). Consistent with the idea that 
these effects are due to improved neovascularization of ischemic limbs, the recovery 
of blood flow is improved by antagomir-92a compared to PBS or control antagomirs 
(Fig. 3.24 B). Likewise, the number of capillaries and the number of smooth muscle 
actin-positive arterioles is increased after antagomir-92a treatment (Fig. 3.24 C/D) 
indicating that antagomir-92a enhances perfusion and functional recovery of 
ischemic limbs.  
 
3.13  Antagomir-92a improves functional recovery after acute     
myocardial infarction 
 
To determine the effect of antagomir-92a treatment on functional recovery after acute 
myocardial infarction, the left coronary artery was occluded and left ventricular (LV) 
function was determined by Millar catheterization after 14 days (Table 3.2). 
Antagomir-92a treatment improves LV systolic and diastolic function as evidenced by 
increases of dp/dtmax and dp/dtmin, and significantly reduced enddiastolic pressure as 
well as tau as a parameter for isovolumic relaxation compared to vehicle controls and 
control antagomir treatment (Table 3.2 and Fig. 3.25 A-C). Representative pressure-
volume loops reflect the functional recovery after antagomir-92a injection compared 
to PBS and antagomir-Co treated mice (Fig. 3.25 D). 
 
  
 
Tabel 3.2 Antagomir-92a improves recovery after acute myocardial infarction    
Antagomir-92a, antagomir-Co or PBS were infused i.v. at day 0, 2, 4, 7 and 9 after ligation of the left 
coronary artery. On day 14, cardiac catheterization was performed for functional analysis by using 
1.4F micromanometertipped conductance catheter (Millar Instruments Inc).  Left ventricular (LV) 
pressure and its derivative (LV dP/dt) were continuously monitored with a multiple recording system. 
AMI operations was performed by Masayoshi Iwasaki and Jana Burchfield. 
All data were acquired under stable hemodynamic conditions.   
AMI: acute myocardial infarction, Antagomir-Co: control antagomir,  
HR: heart rate, LVESP: left ventricular end systolic pressure, LVEDP: left ventricular end diastolic pressure 
* indicates p<0.01 vs sham.  
† and 
†† indicate p<0.05 and p<0.01 vs AMI+PBS, respectively.  
# and 
## indicate p<0.05 and p<0.01 vs AMI+Antagomir-co, respectively. 
 
 
Furthermore, antagomir-92a treatment reduces the infarct size by 44+3% (Fig. 3.26 
A) and significantly augments the number of in vivo perfused lectin-positive vessels 
particularly in the remote and border zone (Fig. 3.26 B). Antagomir-92a treatment 
also increases the number of smooth muscle actin positive vessels by ~1.4-fold (Fig. 
3.26 C). 
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Figure 3.25 Antagomir-92a improves functional recovery after acute myocardial 
infarction 
(A-D) 8 mg/kg bw antagomir -92a (n=8), control antagomirs (n=6), or PBS (n=7) were injected at 
days 0, 2, 4, 7, 9 after induction of myocardial infarction. On day 14, cardiac catheterization was 
performed for functional analysis compared to sham controls as shown in panels A-C, n=5-8. Panel 
D shows representative pressure volume loops. AMI operation was performed by Masayoshi 
Iwasaki and Jana Burchfield. 
 
Having shown that inhibition of miR-92a improves recovery after myocardial 
infarction, we further investigated, if antagomir-92a treatment might have an anti-
apoptotic effect on cardiomyocytes by increasing the number of capillaries and 
smooth muscle actin-positive cells. 
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Figure 3.26 Antagomir-92a reduces infarct size and increases capillary density after 
acute myocardial infarction 
8 mg/kg bw antagomir 92a, control antagomirs, or PBS were injected at days 0, 2, 4, 7, 9 after 
induction of myocardial infarction. On day 14, infarct size was measured, n=3-5. Representative 
images of the apex are shown (A). Capillary density was determined after i.v. infusion of FITC-
conjugated lectin and was quantified in the remote, border and infarct regions of the hearts. (B) 
Quantification of n=6 high power fields per region per group, and (C) representative images of the 
remote region. Arteries were visualized by smooth muscle actin (SMA) staining and quantified per 
cross section, n=3-6. D) Representative images of smooth muscle actin (red) and lectin (green) and 
(E) quantitative analysis of SMA-positive vessels are shown. 
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 Therefore, freshly isolated rat neonatal cardiomyocytes were incubated with 
antagomir-92a or antagomir-Co for 48 h. Then, cardiomyocytes were serum-deprived 
for 24 h by incubation with medium depleted from FCS to induce apoptosis, but 
containing antagomir-92a or antagomir-Co to determine the impact of miR-92a on 
cell death. Apoptotic cells were measured by FACS analysis. However, antagomir-
92a has no effect on cardiomyocyte apoptosis in vitro (Fig. 3.27 A). Additionally, we 
analysed the effect of antagomir-92a treatment on cardiomyocytes in the infarct zone 
in vivo using TUNEL staining. Whereas antagomir-92a shows no effect on 
cardiomyocyte apoptosis in vitro, we observed a significant downregulation of 
apoptosis in vivo (Fig. 3.27 B).   
 
 
Figure 3.27 Effect of antagomir-92a treatment on apoptosis in vitro and in vivo 
A) Rat neonatal cardiomyocytes were pre-incubated with antagomir-92a for 48 h. Then, cells were 
washed and medium was replaced by medium without FCS („starving“) and antagomir-92a or 
control antagomir (each 150 nM) was added again for 24 h.  Apoptotic cells were detected by 
annexin V staining by FACS, n=3. B) miR-92a was inhibited by injecting antagomir-92a (8 mg/kg bw 
at days 0) or antagomir control after ligation of left coronary artery. In order to quantify in vivo 
apoptosis after myocardial infarction in the infarct zone TUNEL staining was performed using 4-µm 
paraffin sections of the heart at day 14, n=4-5.   
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 These data indicate that antagomir-92a improves functional recovery after acute 
myocardial infarction by increasing the number of capillaries and smooth muscle 
actin positive vessels and reducing the number of apoptotic cardiomyocytes in the 
infarct zone. We further addressed the question, if miR-92a expression and activity is 
restricted to endothelial cells exerting anti-apoptotic effects on cardiomyocytes in a 
paracrine manner or if miR-92a has also a functional role in cardiomyocytes. In order 
to clarify this question, we performed an in situ hybridization using frozen sections 
from the heart. A specific 3`DIG labelled LNA probe as well as a scrambled probe as 
negative control and a U6 probe as positive control were used.  
 
 
Figure 3.28 Expression profile of miR-92a 
A) After ligation of the left coronary artery, antagomir-92a or control antagomir (Antagomir-Co) were 
injected i.v. at a concentration of 8 mg/kg bw at day 0. Hearts were harvested at day 2 and in situ 
hybridization on frozen sections was performed using a specific 3´DIG-labelled probe for miR-92a. 
U6 served as positive control, a scrambled probe was used as negative control. Sections were 
counterstained with lectin ex vivo (green) and DAPI (blue).  White arrows indicate miR-92a 
expressing endothelial cells in control antagomir-treated mice, red  arrows indicate U6-positive  non-
endothelial cells. Scale bar indicates 20 µm. B) Human umbilical vein endothelial cells (HUVEC), 
human coronary artery endothelial cells (HCAEC), human aortic fibroblasts (HAF), human cardiac 
myocytes (HCM), human smooth muscle cells (SMC) and CD34+ cells were cultured in vitro. RNA 
was isolated and expression of miR-92a was assessed by real time PCR. U48 served as loading 
control. 
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 Co-staining with Lectin to visualize capillaries indicates a higher expression of miR-
92a in endothelial cells compared to cardiomyocytes (Fig. 3.28 A). Administration of 
antagomir-92a abolished the staining demonstrating that the miR-92a probe is 
specific. Moreover, we analysed the expression of miR-92a in various cell types such 
as different endothelial cells, smooth muscle cells, fibroblasts and cardiomyocytes. 
As shown in Fig. 3.28 B, human umbilical vein endothelial cells express miR-92a on 
a much higher level in comparison to microvascular or artery endothelial cells as well 
as smooth muscle cells, fibroblasts and cardiomyocytes.   
 
3.14  Genes regulated by miR-92a 
 
Having shown, that miR-92a is critically involved in angiogenic processes in vitro and 
in vivo, we further addressed the question, which potential miR-92a targets might be 
responsible for the observed effects.  
 
 
Tabel 3.3 Potential miR-92a targets 
Targets were predicted in silico using TargetScan, PicTar or miRanda software. 
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As shown in Table 3.3, in silico target prediction of miR-92a revealed several targets 
involved in angiogenesis, whose deletion causes, in most cases, embryonic lethality 
by a defect in vascular development.  78 
 
The targets predicted in silico included several regulators of endothelial cell functions 
and vessel growth, such as the Integrin subunits α5 and αv, which mediate cell-
matrix interactions, anti-apoptotic signaling and cell migration (Francis et al., 2002; 
Urbich et al., 2002; Yang and Korsmeyer, 1996). Furthermore, other predicted pro-
angiogenic targets include the histone deacetylase SIRT1 (Imai et al., 2000; Potente 
et al., 2007), the small GTP-binding protein RAP1, an angiogenesis-mediating 
protein involved in Integrin signaling (Chrzanowska-Wodnicka et al., 2008), the 
sphingosin-1-phophate receptor 1 (S1P1) (Paik et al., 2001) and the mitogen 
activated kinase kinase 4 (MKK4). In order to determine whether the predicted 
targets are indeed regulated by miR-92a, we overexpressed miR-92a in HUVEC 
using pre92 or control, isolated RNA after 48h and performed an Affymetrix mRNA 
gene expression array. Upregulation of miR-92a causes a more than 1.25-fold 
downregulation of ~7000 genes (53.000 genes were analysed in total) in comparison 
to control (data not shown). Quantification of the mRNA expression revealed, that 
many genes involved in angiogenic signaling are downregulated by miR-92a 
overexpression (Fig. 3.29 A).  
In order to confirm these results on protein level, we performed Western blotting 48 h 
after transfection with pre92 or control precursor and demonstrate that especially 
Integrin α5 and eNOS are significantly reduced in HUVEC overexpressing miR-92a 
(Fig.3.29 B). Additionally, we observed a downregulation of MKK4 and SIRT1 protein 
(Fig. 3.29 B). Accordingly, overexpression of miR-92a results in the decrease of 
Integrin α5 protein on the cell surface as well as in total lysates as measured by 
FACS analysis (Fig. 3.29 C).  
  
Figure 3.29 Target genes downregulated on protein level 
HUVEC were transfected with pre92 or control. A) Protein expression determined by Western 
blotting using antibodies against Integrin α5, eNOS, MKK4 and SIRT1. Quantitative analysis and 
representative images are shown, n=3-4. B) Integrin α5 expression on the surface was measured 
using FACS analysis, n=3. 
 
 
3.15 Integrin  α5 is a direct target of miR-92a 
 
Given the pivotal role of Integrin α5 in vascular development and angiogenesis and 
its profound regulation by overexpression of miR-92a, we investigated whether 
Integrin α5 is a direct target of miR-92a.  The 3´UTR of Integrin α5 contains one 
conserved predicted binding site for miR-92a (Fig. 3.30 A). We therefore cloned a 
fragment of the Integrin α5 3´UTR sequence containing 4x the binding sites of miR-
92a or a fragment containing the mutated seed sequence in the 3`UTR of the 
Luciferase reporter and examined luciferase activity after co-transfection with miR-
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 92a in HEK293 cells. Indeed, miR-92a overexpression reduces luciferase activity 
(Fig. 3.30 B), indicating that Integrin α5 is a direct target of miR-92a.  
 
 
Figure 3.30 Integrin α5 is a direct target of miR-92a 
A) Schematic illustration of miR-92a seed sequence in the Integrin α5 3`UTR. Green indicates the 
mutated nucleotides. B) Luciferase normalized to Renilla activity measured in homogenates of 
HEK cells transfected with the wild type (wt) or mutated luciferase constructs and pre92 or control 
precursor, n=3-4. 
 
 
Mutation of the target sequence results in a higher basal expression indicating 
stabilization possibly by protecting against endogenous miR-92a and reduces the 
downregulation by pre-miR-92a (Fig. 3.30 B). 
Having shown that Integrin α5 is a direct target of miR-92a, we further addressed the 
question, if the reduced expression of Integrin α5 by miR-92a may contribute to the 
inhibition of sprout formation in vitro.  
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Figure 3.31 Impaired sprouting by miR-92a overexpression is mediated by Integrin 
α5 
HUVEC were cotransfected with Integrin α5 or scrambled siRNA and PBS or antagomir-92a. The 
cumulative sprout length per spheroid was measured 24 h after embedding spheroids in the 
collagen matrix. 
 
 
Therefore, we inhibited miR-92a expression using antagomir-92a and co-silenced 
Integrin α5 by siRNA and found that antagomir-92a only stimulates sprouting in the 
presence but not in the absence of Integrin α5 (Fig. 3.31). 
In order to investigate the regulation of Integrin α5 by miR-92a in vivo, we inhibited 
miR-92a expression by i.v. injection of antagomir-92a or control antagomir. Two days 
after injection, Integrin α5 expression in the muscle was quantified using real-time 
PCR and histological sections. In accordance with our in vitro data, inhibiting miR-
92a by antagomir-92a treatment in vivo increases the expression of Integrin α5 
mRNA (Fig. 3.32 A) and protein (Fig. 3.32 B) in the vasculature of non-ischemic 
muscle tissue as shown by staining with a specific Integrin α5 antibody. 
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Figure 3.32 Antagomir-92a upregulates Integrin α5 expression in vivo 
A) Antagomir-92a (8 mg/kg bw, i.v.) or antagomir-Co were injected once directly after induction of 
ischemia. The expression of Integrin α5 was determined by real time PCR in non-ischemic muscle 
in antagomir-92a or control antagomir-treated mice and was compared to non-treated controls, n=6-
8. 
§p<0.05 versus non-treated control muscle,
 # p<0.05 compared to antagomir controls. B) 
Immunstaining against Integrin α5 (red) of non-ischemic muscle sections from mice treated with 
antagomir-92a or controls. 
 
 
In summary, these data indicate that Integrin α5 is a key regulator of antagomir-92a-
mediated improved angiogenesis and therefore recovery after hind limb ischemia and 
acute myocardial infarction.  
To identify genes, which might be secondarily regulated by Integrin α5, we performed 
an additional Affimetrix profiling using RNA from HUVEC treated with Integrin α5 
siRNA (Table 3.4) and compared the results with the previously performed pre92 
Affimetrix chip.  
Several genes were identified, which are downregulated by pre92 and Integrin α5 
siRNA suggesting that these genes are indirectly regulated by miR-92a-dependent 
downregulation of Integrin α5. The most prominent example is the regulation of 
eNOS expression, which is downregulated by miR-92a and Integrin α5 siRNA 
indicating that eNOS downregulation in response to miR-92a overexpression may 
occur as a consequence of Integrin α5 mRNA degradation. 
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Table 3.4 Summary of genes downregulated by miR-92a and Integrin α5   
HUVEC were transfected with pre92 and control or siRNA against Integrin α5 and scrambled 
siRNA. 48 h after transfection RNA was isolated and subjected to an Affimetrix mRNA chip. 
Selected genes which are downregulated by pre92 are shown. Light blue represents directly 
predicted targets, which are not regulated by Integrin α5 siRNA, blue represents genes, which are 
downregulated by pre92 and Integrin α5 siRNA indicating that these targets might be indirectly 
regulated by miR-92a-dependent downregulation of Integrin α5. Dark blue represents genes 
downregulated by pre92, which are not predicted as direct targets and are not regulated by Integrin 
α5  
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Furthermore, we identified a large group of regulated genes, which are not predicted 
to be miR-92a targets and are not regulated by Integrin α5 siRNA suggesting that 
these genes might be regulated by other direct miR-92a target genes. 85 
 
4  Discussion 
 
MicroRNAs are a recently discovered class of highly conserved, non-coding small 
RNAs that regulate gene expression on the post-transcriptional level by binding to 
the target mRNA leading either to translational repression or mRNA degradation 
(Bartel, 2004). MicroRNAs control various physiological and pathophysiological 
processes such as cardiogenesis and oncogenesis (Bartel, 2004; van Rooij et al., 
2007; Ventura et al., 2008; Zhao et al., 2007). Additionally, several studies have 
dissected the role of miRNAs in skeletal muscle proliferation and differentiation, brain 
morphogenesis, and hematopoietic lineage differentiation (Chen et al., 2004; 
Giraldez et al., 2005; Zhao et al., 2005). However, at the beginning of this study, the 
involvement of miRNAs in vascular signaling and function was unknown. Therefore, 
the major aim of this study was the analysis of the general role of microRNAs for 
endothelial cell biology. Moreover, the function of specific microRNAs highly 
expressed in EC should be investigated in detail.  
 
4.1  MicroRNAs are crucial regulators of endothelial cell biology 
 
4.1.1 Role of Dicer and Drosha in endothelial cells 
The present study demonstrates for the first time that the enzymes Dicer and Drosha, 
which are the major enzymes involved in miRNA biogenesis, play a decisive role in 
endothelial cell biology. Immunostainings and Western blot analysis revealed that 
Dicer and Drosha are expressed in endothelial cells, whereby Drosha is restricted to 
the nucleus and Dicer is mainly localized in the cytoplasm. Transient silencing 
efficiently blocking Dicer and Drosha on mRNA and protein level demonstrates that 
both enzymes are involved in the regulation of angiogenesis in vitro. Additionally, 
inhibition of Dicer specifically impairs migration and viability of endothelial cells and 
reduces in vivo angiogenesis.  
In summary, our data provide evidence for an important role of Dicer and Drosha for 
endothelial cell functions. The profound impairment of in vitro angiogenesis in Dicer 
deficient endothelial cells is consistent with findings, which were published 86 
 
simultaneously with the data of the present study (Giraldez et al., 2005; Suarez et al., 
2007; Yang et al., 2005).  
However, there have been also several inconsistencies between the different studies. 
While the migration of Dicer-deficient endothelial cells on collagen matrix is not 
affected in the study of Suarez and his collegues (Suarez et al., 2007), migration is 
significantly impaired when fibronectin was used as matrix as shown in our study. It is 
conceivable that depletion of Dicer differentially modifies Integrin receptors, thereby 
selectively impairing fibronectin matrix-dependent cell functions. Furthermore, Dicer 
knockdown causes profound dysregulation of angiogenesis-related genes in vitro and 
in vivo. Despite the requirement of Dicer for vascularization, crucial regulators of 
angiogenesis, for instance vascular endothelial growth factor (VEGF)  and its 
receptors FLT1 and KDR have been shown to be upregulated (Suarez et al., 2007; 
Yang et al., 2005) . In contrast, our study did not reveal a role of Dicer in the 
regulation of KDR expression, which might suggest that this regulation is a highly 
dynamic process. Furthermore, protein levels of TIE1 are decreased in Dicer 
ex1/2 
embryos (Yang et al., 2005), whereas its expression is strongly enhanced in Dicer-
depleted cultured endothelial cells (Suarez et al., 2007). This phenomenon might be 
explained by the complex mixture of miRNAs being spatiotemporally expressed 
during development compared to isolated endothelial cells in culture. 
 
Interestingly, the knockdown of Dicer exerts more profound effects on endothelial 
sprout formation in vitro and in vivo compared to Drosha, although Drosha acts 
upstream of Dicer in miRNA biogenesis. To exclude that the distinct biological 
response is caused by a methodological problem, control experiments were 
performed to confirm a similar efficiency of the downregulation on protein and mRNA 
level. Moreover, the findings were reproduced using a second siRNA sequence 
excluding a nonspecific effect of one of the sequences. Furthermore, the genetic 
downregulation of Drosha efficiently reduced the expression of about 42% of the 
detected miRNAs as shown in a microRNA profiling indicating that the minor 
phenotypic alteration in Drosha siRNA-transfected cells is not related to an 
insufficient reduction of Drosha enzymatic activity.  
An explanation for the profound differences between Dicer and Drosha silenced cells 
could likely be due to the selective impairment of AKT signaling in Dicer siRNA 
treated cells. Moreover, the distinct effects of Dicer versus Drosha may be related to 87 
 
other biological properties of Dicer, namely its role in the formation and maintenance 
of heterochromatin  (Volpe et al., 2002), which might also affect endothelial cell 
functions independent of the reduction of miRNA processing. Moreover, a recently 
described Drosha-independent microRNA processing pathway could compensate for 
the loss of Drosha (Okamura et al., 2007; Ruby et al., 2007). Additionally, the minor 
role of Drosha compared to Dicer on sprouting might alternatively be explained by a 
concomitant effect on anti-apoptotic or pro-angiogenic genes, which might be less 
affected by Dicer siRNA. A downregulation of miRNAs targeting anti-apoptotic or pro-
angiogenic genes might lead to an upregulation of protective and pro-angiogenic 
proteins in Drosha-silenced endothelial cells and may partially compensate for the 
increase in angiogenesis inhibitors. It is well established that angiogenesis is 
regulated by a balance of pro- or anti-angiogenic genes. A disturbance of this critical 
balance by interfering with various miRNAs, each of which inhibiting translation or 
transcription of multiple target mRNAs, may well explain differences in the 
phenotype. 
 
Profiling of miRNA expression in endothelial cells, as it has been performed in the 
present study, additionally provides a tool to identify potential important miRNAs in 
endothelial cell biology. Strikingly, the relative expression of about 60% of the 
miRNAs was below the detection limit indicating that the majority of the miRNAs are 
downregulated in endothelial cells. This is consistent with the concept that miRNAs 
are differentially expressed during development and control lineage commitment 
(Chen et al., 2004; Giraldez et al., 2005; Sempere et al., 2004; Wienholds et al., 
2005). A cell type specific regulation of miRNA expression may contribute to tissue 
and cell type specific patterning of gene expression. However, to exclude that the 
results are due to false-negative detection, the data were selectively confirmed by 
RT-PCR demonstrating that several miRNAs such as miR-142-3p are not detectable 
in EC (data not shown). The high expression of miR-221 is in accordance with a 
recent study demonstrating that miR-221 may affect the angiogenic properties of 
endothelial cells by regulating c-kit, the receptor for the cytokine stem cell factor 
(SCF) (Poliseno et al., 2006). Consistently, c-kit expression was significantly 
increased in Dicer and Drosha siRNA transfected cells. Moreover, according to other 
recently published studies miR-126 and miR-130, which has been shown to play a 
crucial role in angiogenic processes, are highly expressed in endothelial cells (Chen 88 
 
and Gorski, 2008; Fish et al., 2008; Wang et al., 2008). Thus, the data of the present 
miRNA array analysis allows to selectively evaluate the function and regulation of 
endothelial cell-enriched miRNAs in future studies.  
Surprisingly, the downregulation of Drosha and Dicer only affects a subset of 
miRNAs. Based on the assumption that these two enzymes are essential for miRNA 
processing, one would have expected to see a downregulation of the majority of 
miRNAs. However, in accordance with our data, others also reported that only a 
subset of miRNAs is reduced after Dicer downregulation (55% (Cummins et al., 
2006) and 15-59% (Giraldez et al., 2005)). The incomplete inhibition of miRNAs 
might be explained by an insufficient downregulation of the enzymes or a higher 
stability of some of the miRNAs exceeding the transient effect of Drosha or Dicer 
downregulation by siRNA. Finally, the data should be interpreted with caution due to 
the limitation of the miRNA array technology. Although the assays preferentially 
detect mature miRNAs, the discrimination of pri-, pre- and mature miRNAs requires 
confirmation by Northern blotting. The low sensitivity of Northern blot, however, limits 
its general use.  
 
4.1.2 Let-7f and miR-27b are regulated by Dicer and Drosha 
 
Based on the miRNA profiling performed after inhibition of Dicer and Drosha we 
could identify several miRNAs including the let-7 cluster and miR-27b, which were 
downregulated by both, Dicer and Drosha knockdown. 
Using in silico prediction of targets for the highly expressed, and by Drosha and Dicer 
siRNA downregulated let-7 cluster, we identified several potential interesting genes 
including thrombospondin-1 (TSP1). TSP1 is a potent endogenous inhibitor of 
angiogenesis  (Iruela-Arispe et al., 1991). Upregulation of TSP1 in endothelial 
progenitor cells contributes to impaired vasculogenesis in diabetic mice (Ii et al., 
2006). Consistent with a predicted regulatory role of the let-7 cluster for targeting 
TSP1, Drosha and Dicer silencing augmented TSP1 expression. Given that TSP1 is 
a potent angiogenesis inhibitor, its upregulation might contribute to the impairment of 
angiogenesis after Drosha or Dicer downregulation. Because of its most significant 
downregulation by Dicer and Drosha compared to other let-7 cluster members we 
selected let-7f for further studies. A let-7f inhibitor, however, increased TSP1 89 
 
expression only about 15% indicating that other factors (e.g. other let-7 family 
members) may in part compensate for the loss of let-7f (data not shown).  
The angiogenesis suppressive effect of Dicer and Drosha downregulation may in part 
be related to the augmentation of the angiogenesis inhibitor TSP1. Since a variety of 
miRNAs are highly expressed and dysregulated by Drosha and/or Dicer siRNA and 
each miRNA has multiple pro- and anti-angiogenic targets, further studies are 
required to dissect the complex process of posttranscriptional regulation of gene 
expression during angiogenesis. 
 
4.2  Regulation and function of miR-92a 
 
4.2.1 The miR-17-92 cluster is highly expressed in EC 
 
As shown in the first part of the study, inhibition of miRNA processing by genetic 
knockdown of Dicer and Drosha expression impairs endothelial cell functions and 
angiogenesis (Giraldez et al., 2005; Suarez et al., 2007; Yang et al., 2005) 
suggesting an important role of miRNAs for endothelial cell biology. Recently, a few 
miRNAs have been identified to stimulate (let-7f, miR-27b, miR-130 (Chen and 
Gorski, 2008)) or inhibit (miR-221 and miR-222 (Poliseno et al., 2006)) endothelial 
sprout formation in vitro. Additionally, two recent studies demonstrated the in vivo 
contribution of miR-126, which is highly expressed in endothelial cells, to angiogenic 
signaling and vascular integrity (Fish et al., 2008; Wang et al., 2008). 
In this regard, we mainly focused in the second part of the study on one specific 
miRNA, miR-92a, and its involvement in endothelial cell function. MiR-92a is a 
member of the conserved miR-17~92 cluster consisting of miR-17, miR-18a, miR-
19a, miR-20a, miR-19b-1 and miR-92a (Ventura et al., 2008), which was shown to be 
upregulated in tumors (Cerny and Quesenberry, 2004; He et al., 2005; Venturini et 
al., 2007). Its overexpression in tumor cells promotes tumor angiogenesis (Dews et 
al., 2006). The oncogenic and pro-angiogenic functions of the miRNAs encoded by 
the cluster have been attributed to miR-18 and miR-19, which inhibit apoptosis of 
tumor cells (Ventura et al., 2008; Wang et al., 2008) and promote tumor 
angiogenesis by suppressing the release of soluble anti-angiogenic factors by tumor 
cells, thereby affecting endothelial cells in a paracrine manner (Dews et al., 2006). 90 
 
We selected miR-92a because of the high expression shown in the expression 
profile, the previously proposed role of the miR-17~92 cluster in tumor angiogenesis, 
and the several predicted miR-92a targets involved in angiogenic signaling such as 
Integrin α5, Integrin αv and SIRT1. 
4.2.2 miR-92a inhibits angiogenesis in vitro and in vivo 
 
In contrast to the paracrine pro-angiogenic effects of miR-18 and miR-19 (Dews et 
al., 2006), two other members of the miR-17-92 cluster, overexpression of the miR-
92a using miR-92a precursor (termed pre92) in HUVEC unexpectedly blocks sprout 
formation in a three-dimensional model of in vitro angiogenesis and inhibits vascular 
network formation in matrigel assays. The development of tubular structures in a 
spheroid model and matrigel network forming assay depends on several cellular 
processes, especially migration, proliferation and apoptosis. Indeed, overexpression 
of miR-92a reduces basal and VEGF-induced EC migration and impairs adhesion to 
fibronectin.  Cytotoxic effects of the pre92 transfection could be excluded by 
measuring viability and cell proliferation under basal conditions and serum depletion. 
However, cellular assays reflect only inadequately the complexicity of angiogenic 
processes  in vivo. In order to reflect the in vivo situation, we implanted pre92-
transfected HUVEC in matrigel plugs in nude mice. MiR-92a overexpression 
efficiently blocks the number of invading cells and formation of capillary-like 
structures observed in matrigel plugs containing control-transfected HUVEC. 
Additionally, in vivo perfused lectin-positive vessels and the hemoglobin content (as a 
surrogate marker of perfusion) were significantly reduced in the explanted matrigel 
plugs. These results indicate that overexpression of miR-92a blocks angiogenesis in 
vitro and in vivo. Consistent with our findings that overexpression of miR-92a inhibits 
angiogenesis  in vitro, downregulation of endothelial miR-92a by 2`O-methyl 
antisense oligonucleotides increases sprout formation in vitro indicating that inhibition 
of miR-92a may represent a novel therapeutic strategy to enhance angiogenesis.  
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4.2.3 MiR-92a is upregulated under ischemic conditions and is
  efficiently suppressed by antagomir-92a treatment in vivo 
 
To block miR-92a expression in vivo, we used so-called antagomirs, which are 
chemically modified antisense oligoribonucleotides developed for inhibition of miRNA 
expression  in vivo (Krutzfeldt et al., 2005). Krutzfeld et al. achieved an almost 
complete knockdown of miR-122 in all tissues except the brain using an antagomir 
directed against miR-122 at the concentration of 80 mg/kg bw. Since we were 
interested in targeting mainly the vasculature, the primary organ taking up 
substances from the blood, we tested different antagomir concentrations, below the 
already published concentration of 80 mg/kg, ranging from 1 to 40 mg/kg bw. 
Injection of 8 mg/kg bw antagomir-92a sufficiently blocks miR-92a expression in 
heart, spleen, liver and muscle. Moreover, Cy3-labelled antagomir-92a at a 
concentration of 8 mg/kg mainly targets the vasculature as shown in histological 
sections. Hence, we choose a concentration of 8 mg/kg for all further in vivo studies.    
 
Consistent with the hypothesis that inhibition of miR-92a augments angiogenesis, 
systemic application of antagomir-92a enhances the number of invading cells and in 
vivo perfused lectin-positive vessels in implanted matrigel plugs. Additionally, it 
significantly increases perfusion measured by hemoglobin content in matrigel plugs. 
Extracellular single-stranded RNA can cause increased vascular permeability by 
mobilizing/stabilizing VEGF and inducing VEGF signaling via the VEGF receptor 2 
(Fischer et al., 2007). In order to exclude off-target effects of antagomir-92a 
treatment, we used two different control antagomirs, both of which having no effect 
on plug vascularization. Based on the fact that one single miRNA potentially targets 
several hundred mRNAs in the cell, subsequently dysregulating a global network of 
genes, we addressed the question, if miR-92a downregulation by antagomir-92a 
might cause toxic effects in healthy mice. However, no obvious side effects were 
determined after 8 mg/kg antagomir-92a infusion for two weeks (data not shown). 
Furthermore, Dr. Olsons group recently presented data showing no toxicity of 
systemic antagomir treatment up to a concentration of 300 mg/kg in mice (MicroRNA 
symposium, Cologne, Germany, 6. March 2008), and previous studies have shown 
that systemic treatment with 3-10 mg/kg LNA-locked anti-miRs are well tolerated in 
non-human primates (Elmen et al., 2008).  92 
 
 
We evaluated the specificity of antagomir-92a treatment by analyzing the expression 
of various other miRNAs including members of the miR-17~92 cluster and closely 
related miRNAs such as miR-92b in the hind limb muscle. Antagomir-92a treatment 
significantly reduces the expression of miR-92a, while not affecting other members of 
the cluster (miR-18a, miR-19a). Furthermore, it slightly, but non-significantly impairs 
the expression of the very closely related miR-92b, which only differs from miR-92a 
by 2 nucleotides. Moreover, miR-24 and miR-93 are not regulated by antagomir-92a. 
These data demonstrate that antagomir-92a treatment specifically reduces the 
expression of miR-92a in vivo without affecting the expression of other related and 
non-related miRNAs, thereby increasing vascularization. 
We further characterized the physiological role of miR-92a for angiogenic processes 
by analysing its time-dependent expression in response to ischemia. Given the anti-
angiogenic role of miR-92a in vitro, it is very astonishing that miR-92a is dramatically 
upregulated in the ischemic limb at day 1 and 2 after induction of hind limb ischemia. 
Moreover, miR-18a expressed by the same cluster and thus controlled by the same 
promoter is upregulated to a lower extend at day 2 and shows another time kinetic of 
regulation in comparison to miR-92a. This phenomenon might be well explained by 
the existence of RNA-binding proteins, e.g. hnRNP A1, which expression is required 
for proper miR-18a processing. HnRNP A1 specifically binds the stem loop of miR-
18a in the primary miR-17-92 transcript, therefore enhancing its processing by 
Drosha (Guil and Caceres, 2007). Furthermore, there is increasing evidence that 
single proteins can bind to the microprocessor complex, thereby 
stabilizing/increasing the cropping of pri-miRNA into pre-miRNA without changing the 
pri-miRNA content (Davis et al., 2008). It is conseivable that proteins, upregulated by 
hypoxia in ischemic tissue, specifically enhance pri-miR-92a processing while other 
members of the cluster are not affected. A potential candidate could be HIF-1α or 
one of its downstream targets (Wang et al., 1995). However, further experiments 
need to be performed in order to clarify this issue. Interestingly, ischemia-induced 
upregulation of miR-92a is completely abrogated 4 days after induction of hind limb 
ischemia suggesting that factors, highly expressed between day 3 and 4 after 
induction of ischemia, might downregulate miR-92a. Since it is well-known that VEGF 
is one of the major pro-angiogenic factors upregulated by ischemia, we investigated 
the regulation of miR-92a expression by VEGF and another pro-angiogenic factor 93 
 
bFGF in further detail (data not shown). Surprisingly, low concentrations of VEGF 
induce a biphasic expression pattern compared to control, upregulate expression of 
miR-92a at 24 hours, and downregulate miR-92a expression at 48 hours. By contrast 
high concentrations of VEGF downregulates the expression of miR-92a at both time 
points (data not shown). In addition and in contrast to VEGF, bFGF increases miR-
92a expression at high concentrations indicating that the regulation of miR-92a 
expression by angiogenic factors is more complex than initially anticipated. As the 
regulation may not only involve the transcriptional regulation of the miR-17~92 
cluster, but also may be influenced by putative effects of growth factor signaling on 
miR-92a stability, further studies are necessary to evaluate the specific role of growth 
factor-mediated regulation of miR-92a expression.  
 
4.2.4 Inhibition of miR-92a promotes angiogenesis and functional 
recovery after ischemia in vivo 
 
Based on our findings that miR-92a, which exhibits anti-angiogenic characteristics as 
shown in vitro and in vivo, is highly upregulated in the early stage of ischemia, we 
tested the effect of miR-92a inhibition by antagomir-92a treatment in a model of hind 
limb ischemia. The intravenous infusion of antagomir-92a immediately after induction 
of hind limb ischemia leads to a significant reduction in toe necrosis compared to 
PBS and antagomir-Co treated mice. Consistent with the idea that these effects are 
due to improved neovascularization of ischemic limbs, the recovery of blood flow is 
increased by antagomir-92a compared to PBS or control antagomirs. Likewise, the 
number of capillaries and the number of smooth muscle actin-positive arterioles is 
increased after antagomir-92a treatment indicating that antagomir-92a improves 
perfusion and the functional recovery of ischemic limbs. Since we confirmed that 
antagomir-92a treatment induces a 1.7-fold increase in arterioles after hind limb 
ischemia, a rescue of necrosis is well conceivable in the context of various published 
results by others. For instance, eNOS overexpression in mice was shown to increase 
capillary density to about 1.5-fold at 2 weeks after limb ischemia (Brevetti et al., 
2003). Moreover, improvement of angiogenesis by pro-angiogenic growth factors has 
previously been shown to improve the functional recovery of limbs after ischemia (Li 
et al., 2005; Lu et al., 2007a). An anti-apoptotic effect by administration of antagomir-94 
 
92a might be another reason for the profound functional improvement after ischemia. 
Although we demonstrate that miR-92a overexpression has no influence on 
apoptosis or proliferation of EC in vitro, it is still unclear to what extend miR-92a 
effects apoptosis of other cells, particularly myocytes. It is feasible that EC, depleted 
from miR-92a, exert paracrine factors on surrounding cells, thereby preventing 
apoptosis. However, further studies are needed, to analyse a potential effect of 
antagomir-92a treatment on other cell types in more detail.  
 
Neovascularization induced by administration of pro-angiogenic factors has been 
presented to be a key factor to enhance functional recovery after myocardial 
infarction (Losordo et al., 1998). To determine the effect of antagomir-92a treatment 
on functional recovery after acute myocardial infarction, the left coronary artery was 
occluded and left ventricular (LV) function was determined by Millar catheterization 
after 14 days. Antagomir-92a treatment improves LV systolic and diastolic function, 
and significantly reduces enddiastolic pressure and tau (a parameter for the 
isovolumetric relaxation time) compared to vehicle controls and control antagomir 
treatment. Furthermore, antagomir-92a treatment reduces the infarct size and 
significantly augments the number of  in vivo perfused lectin-positive vessels 
particularly in the remote and border zone. The increased neovascularization in the 
border and remote myocardium might additionally prevent negative ventricular 
remodelling and improve contractile recovery. Antagomir-92a treatment also 
increased the number of smooth muscle actin positive vessels. Moreover, we 
determined the number of TUNEL-positive cardiomyocytes at 4 days after induction 
of myocardial infarction. Cardiomyocyte apoptosis in the infarct and border zone is 
significantly reduced by antagomir-92a treatment. Considering the notion that we 
could not detect a direct effect of antagomir-92a on cardiomyocyte apoptosis in vitro, 
the inhibition of cardiomyocyte apoptosis likely reflects an improved 
neovascularization in part rescuing ischemic tissue in the border zone. 
Because miRNAs have multiple targets, and since various cells can be differentially 
affected depending on their expressed targets, we addressed the question, if the 
observed improvement in the ischemic models by antagomir-92a is (partially) due to 
cardiac remodeling, repair and regeneration via affecting non-endothelial cells, such 
as muscle, interstitial cells and fibroblasts. To study whether antagomir-92a treatment 
might have direct effects on non-endothelial cell types, we determined the expression 95 
 
of miR-92a in ischemic hearts by in situ hybridization. Interestingly, miR-92a is 
predominantly expressed in cardiac endothelial cells, whereas only minor expression 
can be detected in cardiomyocytes. The specificity of the miR-92a probe was 
evidenced by the reduction of the endothelial miR-92a staining by antagomir-92a 
treatment. In addition, labelled antagomir-92a was preferentially detected in vessels 
but not in cardiomyocytes and antagomir-92a treatment does not affect 
cardiomyocyte apoptosis in vitro. These data suggest that the vascular endothelium 
is likely a key target tissue for the biological actions of antagomir-92a, by neutralizing 
the anti-angiogenic properties of miR-92a. Though we cannot formally exclude the 
possibility that antagomir-92a treatment affects alternative cell types during cardiac 
repair and regeneration, the improved neovascularization and apparent lack of direct 
effects on cardiomyocytes strongly suggests that enhanced neovascularization, at 
least in part, explains the cardioprotective properties of antagomir-92a treatment. 
Therefore, we aim to generate endothelial-restricted miR-92a knockout mice, which 
will help us to elucidate the function of miR-92a specifically for vascular homeostasis. 
 
4.2.5 MiR-92a effects the expression of a variety of pro-angiogenic 
genes 
 
Our data raised the question, which downstream targets of miR-92a might be 
responsible for the observed effects. During the last years, several online available 
databases based on different algorithms have been developed for reliable prediction 
of potential miRNA targets (Maziere and Enright, 2007).  
Two of the commonly used databases are TargetScan (Grimson et al., 2007) and 
PicTar (Krek et al., 2005) based on sequence-complementarity of miRNA and target 
mRNA. The miR-92a targets predicted in silico include several regulators of 
endothelial cell functions and vessel growth, such as the Integrin subunits α5 (Fig. 
4.1) and αv, which mediate cell-matrix interactions, anti-apoptotic signaling and cell 
migration (Francis et al., 2002; Urbich et al., 2002; Yang and Korsmeyer, 1996). 
Furthermore, other predicted pro-angiogenic targets include the histone deacetylase 
SIRT1 (Imai et al., 2000; Potente et al., 2007), the small GTP-binding protein RAP1, 
an angiogenesis-mediating protein involved in Integrin signaling (Chrzanowska-Wodnicka et al., 2008), the sphingosin-1-phophate receptor 1 (S1P1) (Paik et al., 
2001), and the mitogen activated kinase kinase 4 (MKK4). 
 
 
 
 
Figure 4.1 Integrin α5 is a predicted target of miR-92a 
TargetScan, an online available database, predicts targets based on a specific algorithm. The most 
important criteria are the sequence complementarity, conservation of binding sites, location within 
the 3`UTR and target accessibility. Integrin α5 meets all criteria to be a target of miR-92a. 
 
 
 
Overexpression of miR-92a in EC causes dysregulation of ~ 7000 genes after 48 h 
as presented in a microarray expression profile. An explanation for the huge number 
of dysregulated genes might be the relatively high number of directly regulated miR-
92a targets, each in turn involved in different signaling cascades (Fig. 4.2).  
 
Preliminary data suggest that a microarray profiling 24 h after overexpression of miR-
92a is more suitable to detect direct miR-92a targets. Integrin α5, belonging to the 
group of predicted miR-92a target genes, is highly reduced on mRNA level after 24 
and 48 h. Moreover, the predicted targets Integrin αv, S1P1 as well as MKK4 are 
reduced by overexpression of miR-92a. Accordingly, miR-92a overexpression causes 
a significant reduction of Integrin α5 protein level. Having shown that antagomir-92a 
treatment improves neovascularization after ischemia we further investigated, if this 
effect might be due to increased Integrin α5 expression in vivo. Indeed, mRNA and 
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 protein expression of Integrin α5 in muscle is upregulated by administration of 
antagomir-92a. 
 
 
Figure 4.2. miR-92a regulates a whole network of genes 
Genes containing one or more miR-92a binding sites in their 3`UTR (potential target genes) are in 
red. Genes regulated by potential target genes in blue. 
 
 
In order to clarify, which genes are secondarily regulated in response to Integrin α5 
reduction, we performed a second microarray profile after treatment of EC with 
siRNA targeting Integrin α5. As predicted, several putative direct miR-92a targets 
such as MKK4 or S1P1 are not affected by Integrin α5 siRNA. However, a second 
group of genes, which are downregulated by miR-92a despite the lack of target 
sequences in their 3´UTR, are also reduced by siRNA against Integrin α5. Hence, 
these genes might be secondarily regulated as a consequence of Integrin α5 
downregulation. The most prominent example is the regulation of endothelial NO-
synthase (eNOS), which controls vascular tone and is essential for postnatal 
neovascularization (Murohara et al., 1998; Palmer et al., 1987). eNOS is 
downregulated by miR-92a overexpression and Integrin α5 siRNA indicating that 
eNOS downregulation in response to miR-92a overexpression may occur as a 
consequence of Integrin α5 mRNA degradation.  
However, we are aware that the analysis of mRNA expression gives only limited 
information about the regulation of potential target genes. Although it has been 
shown that animal miRNAs can affect mRNA levels either by sharing almost 
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complete complementarity (Yekta et al., 2004) or also partial base-pairing  (Lim et al., 
2005) with their target site, they exert their effects largely via post-transcriptional 
inhibition of protein synthesis (Pillai et al., 2007). Thus, a technique is needed to 
measure directly genome-wide changes in protein synthesis shortly after changes in 
miRNA expression. Recently, a new method has been developed to overcome this 
problem, the stable isotope labeling with amino acids in cell culture (SILAC). Using 
the SILAC technology, proteins are metabolically labelled by cultivating cells in 
growth medium containing heavy isotope versions of essential amino acids and 
subsequently analysed by mass spectrometry (Selbach et al., 2008; Vinther et al., 
2006). First data suggest that a miRNA can, either by direct or indirect effects, tune 
protein synthesis from thousands of genes (Selbach et al., 2008). 
On the basis of the crucial role of Integrin α5 in vascular development and 
angiogenesis (Francis et al., 2002; Yang et al., 1993), we further investigated the 
direct regulation of Integrin α5 by miR-92a. Cloning of miR-92a seed sequence of the 
Integrin α5 3`UTR in a Luciferase reporter construct followed by overexpression of 
miR-92a demonstrates a direct regulation of Integrin α5 by miR-92a. The specificity 
of mRNA-miRNA binding was proved using mutated seed sequences.   
Demonstrating that Integrin α5 is a direct miR-92a target, we addressed the relevant 
question, if Integrin α5 contributes to miR-92a-mediated impairment of angiogenesis. 
Remarkably, inhibition of miR-92a stimulates sprouting of EC in vitro only in the 
presence but not in the absence of Integrin α5, demonstrating that Integrin α5 is a 
functionally relevant down-stream target of miR-92a in endothelial cells.  
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5  Conclusion 
 
Dicer and Drosha are the major enzymes involved in microRNA processing. Using 
siRNA targeting Dicer and Drosha, thereby downregulating a substantial number of 
microRNAs in EC, we demonstrate a crucial role of both enzymes in angiogenic 
processes. Interestingly, Dicer inhibition exerts more profound effects on processes 
like migration and viability of EC in comparison to Drosha inhibition. Moreover, Dicer 
effects  in vivo angiogenesis, a process which is unaffected by Drosha. This 
discrepancy might be partially due to the involvement of Dicer in other cellular 
processes like heterochromatin formation and to the fact that Dicer and Drosha target 
mainly different subsets of microRNAs.        
In addition, we identified miR-92a as a novel endogenous repressor of the 
angiogenic program in EC, which impairs their angiogenic functions in vitro and in 
vivo. Consistent with these data, blocking miR-92a by systemic infusion of 
antagomirs enhances neovascularization and functional recovery after ischemia in 
vivo. At first sight, the anti-angiogenic function of miR-92a in EC appears to 
contradict the previously identified anti-apoptotic and pro-angiogenic activities of the 
miR-17~92 cluster in tumor cells.  However, this apparent discrepancy might be well 
rationalized by a predominant function of miR-18a and miR-19a in tumor cells, which 
are responsible for the tumorigenic and non-cell autonomous pro-angiogenic 
functions of the miR-17~92 cluster (Dews et al., 2006). Instead, miR-92a expression 
is specifically upregulated in ischemic tissues and appears to cell-autonomously 
repress the angiogenic potential of EC. Among the various targets and verified 
regulated genes identified by microarray, we confirmed the downregulation of Integrin 
α5 in vitro and in vivo. The relevance of this miR-92a target is evidenced by severe 
vascular defects in the absence of Integrin α5 (Francis et al., 2002; Yang et al., 
1993). In addition, endothelial miR-92a interferes with the expression pattern of 
genes controlling key EC functions at various levels, some of which, e.g. eNOS, 
might be secondarily affected by directly targeted genes.   
 
Figure 4.3. Antagomir-92a improves functional recovery after ischemia 
 
 
Obviously, our data do not formally exclude effects of antagomir-92a on perivascular 
and other cell types, but surely include effects on EC. Regardless of this, the capacity 
of miR-92a to target various downstream effectors might be an advantage of miRNA-
based therapeutic strategies and may overcome the limited therapeutic capacity of 
single growth factor or single gene therapies in ischemic disea 
ses, since the highly organized process of vessel growth, maturation and functional 
maintenance is well known to require the fine-tuned regulation of a set of genes (Fig. 
4.3). 
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6  Zusammenfassung 
 
 
Angiogenese, die Bildung von Kapillaren aus bereits existierenden Gefäßen, ist ein 
wichtiger physiologischer Prozess zur Wundheilung und Wiederherstellung des 
Blutflusses nach Verletzung. Das Ziel der vorliegenden Arbeit war die genaue 
Untersuchung der Rolle von microRNAs in angiogenen Prozessen. 
MicroRNAs sind kleine, einzelsträngige RNA Moleküle, welche die Genexpression 
durch Bindung an die messenger RNA (mRNA) von Zielgenen und darauffolgenden 
Degradierung der mRNA oder Repression der Translation regulieren. Die Inhibition 
der microRNA-prozessierenden Enzyme Dicer und Drosha in Endothelzellen führt zu 
einer Dysregulation der microRNA Expression und zu einer signifikanten Reduktion 
der Angiogenese in vitro. Im Gegensatz zu Drosha, dessen Inhibition keinen Effekt 
auf die in vivo Angiogenese zeigt, führt die Inhibition von Dicer auch in einem in vivo 
Angiogenese-Modell zu einer deutliche reduzierten Einsprossung von Gefäßen. 
Zusammenfassend sprechen diese Daten für eine wichtige Rolle von microRNAs in 
der Endothelzellbiologie. 
Der zweite Teil der vorliegenden Arbeit beschränkte sich auf die Untersuchung einer, 
in Endothelzellen hoch exprimierten microRNA, miR-92a. MiR-92a ist ein Mitglied 
des miR-17-92 Clusters, für den bereits eine Rolle in der Tumorangiogenese 
beschrieben ist. Die Überexpression der miR-92a in Endothelzellen führt zu einer 
signifikanten Hemmung der Angiogenese, sowie reduzierter Adhäsion und Migration 
auf Fibronektin. Zudem wird die Einsprossung von Gefäßen in Matrigel Plugs 
deutlich gehemmt. In Übereinstimmung hierzu führt die systemische Hemmung der 
miR-92a mit Hilfe von modifizierten antisense Oligoribonukleotiden (Antagomir-92a) 
im Mausmodell zu einer Stimulation der Einsprossung von Gefäßen in Matrigel 
Plugs. In klinisch relevanten Modellen, wie dem Hinterlaufischämie-Modell und dem 
akuten Myokardinfarkt-Modell, führt die Behandlung mit Antagomir-92a zu einer 
funktionelle Verbesserung. Immunohistologische Analysen ergaben, dass in den 
Antagomir-92a behandelten Tieren sowohl die Anzahl der Kapillaren als auch der 
größeren Gefäße deutlich erhöht ist. Obwohl wir einen direkten Effekt der Antagomir-
92a Behandlung auf die Myozyten zum jetzigen Zeitpunkt nicht auschließen können, 
weisen unsere Daten definitiv auf eine Stimulation der Angiogenese hin. 102 
 
Nachdem wir sowohl in vitro als auch in vivo zeigen konnten, dass miR-92a 
maßgeblich an angiogenen Prozessen beteiligt ist, stellten wir uns die Frage nach 
den zugrunde liegenden Zielgenen. Es zeigte sich, dass miR-92a neben einer 
größeren Anzahl pro-angiogener Faktoren die Integrin Untereinheit α5 sowohl in vitro 
als auch in vivo reguliert. Desweiteren konnten wir mit Hilfe eines Luciferase Assays 
die direkte Regulation von Integrin α5 durch miR-92a zeigen. 
Zusammenfassend deuten diese Daten daraufhin, dass Integrin α5 ein 
Schlüsselregulator der Antagomir-92a-vermittelten Angiogenese ist und somit 
unmittelbar an der Verbesserung nach Hinterlaufischämie und akutem 
Myokardinfarkt beteiligt ist. 
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7  Abbreviations 
 
bFGF       Basic fibroblast growth factor 
bp     Base  pairs 
BrdU     Bromodeoxyuridine 
BSA     Bovine  serum  albumin 
bw     body  weight 
CAD     Coronary  artery  disease 
CAM     Cell  adhesion  molecules 
cDNA     complementary  DNA 
Co     Control 
CTGF       Connective tissue growth factor 
CM-Dil   Chloromethylbenzamido derivative of Dil 
Cy3     Carbocyanine 
DAPI     4',6-diamidino-2-phenylindole 
DIG     Digoxigenin 
DTT     Dithiothreitol 
DNA     Desoxyribonucleic  acid 
eNOS     endothelial  NO  synthase 
EC     Endothelial  cells 
EBM     Endothelial basal medium 
FACS     Fluorescence-activated  cell  sorting 
FCS     Fetal  calf  serum 
FITC     Fluorescein  isothiocyanate 
FLT1     VEGF  receptor  1 
g     grams  or  g  force 
GAPDH     Glyceraldehyde-3-phosphate  dehydrogenase 
H&E stain      hematoxylin and eosin stain 
HAF        Human aortic adventitial fibroblasts 
HCl     Hydrochloric  acid 
HCM     Human  cardiac  myocytes 
HEK293     Human  embryonal kidney epithelial cells 
HMVEC     Human  microvascular endothelial cells 104 
 
HUVEC     Human  umbilical vein endothelial cells 
i.v.     intra  venous 
Kb     Kilobase 
kDa     Kilodalton 
KDR     VEGF  receptor  2 
LNA     Locked  nucleic  acids 
LV     Left  ventricular 
miR     microRNA 
MKK4       Mitogen-activated kinase kinase 4 
mRNA     messenger  RNA 
n     Number  of  experiments 
n.s.     Not  significant 
NO     Nitric  oxide 
OD     Optical  density 
PBS     Phosphate  buffered  saline 
PMSF     Phenylmethylsulfonylfluorid 
RISC     RNA-induced  silencing  complex 
RNA     Ribonucleic  acid 
RT        Room temperature or reverse transcription 
SDS     Sodium  dodecyl  sulfate 
SEM        Standard error of the mean 
siRNA     Small  interfering  RNA 
SIRT1     Sirtuin  1 
SMC        Human aortic smooth muscle cells 
TIE1        Tyrosine kinase receptor 1 
TNF     Tumor  necrosis  factor 
TSP1     Thrombospondin  1 
TUNEL Terminal  deoxynucleotidyl transferase-mediated uridine 5′-
triphosphate-biotin nick end-labeling 
UTR     Untranslated  region 
VEGF       Vascular endothelial growth factor 
vWF     von-Willbrand  factor 
Wt     Wildtype 
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